Section 3 of 6
Product information and disease description
479 evidence topics · 139 sources
Product description
Phase of product development
Summary: regulatory and development status as of September 2026
Tovorafenib is approved in the United States (accelerated approval, 23 April 2024), the European Union (conditional marketing authorisation, April 2026), and Japan (16 September 2026). The US and EU indications are limited to relapsed or refractory (EU: progressed after one or more prior systemic therapies) pediatric low-grade glioma with a BRAF fusion or rearrangement or BRAF V600 mutation, based on the single-arm phase 2 FIREFLY-1 trial. The FDA listed the accelerated approval as ongoing (clinical benefit not yet verified) as of 16 September 2026. No approved indication, supplemental new drug application, or EU variation for first-line use was identified. The first-line trial LOGGIC/FIREFLY-2 (tovorafenib vs standard-of-care chemotherapy) completed enrollment of approximately 400 participants in May 2026; the sponsor expects topline data by mid-2027. FIREFLY-2 is also the confirmatory trial for the US accelerated approval (interim report due April 2028, final report April 2032) and the specific obligation for the EU conditional authorisation (final report due 30 April 2032). The EMA overview page gives 20 April 2026 as the authorisation date, while the Ipsen announcement is dated 22 April 2026. Day One Biopharmaceuticals became a wholly owned subsidiary of Servier after the tender offer closed on 22 April 2026.
United States: accelerated approval for relapsed or refractory pLGG
United States: approval pathway stated in the approval letter
United States: expedited programs and designations
United States: breakthrough therapy and orphan designation dates
United States: rare pediatric disease priority review voucher
United States: August 2025 labeling supplements
United States: accelerated approval status in September 2026
First-line pLGG: FIREFLY-2 enrollment completion and expected data timing
First-line pLGG: FIREFLY-2 status at the time of the EU assessment
Regulatory status: Submission planned; FIREFLY-2 topline data expected by mid-2027, with a potential first-line approval in 2028
Launch
No evidence found.
European Union: conditional marketing authorisation
European Union: assessment procedure and orphan designation
Japan: marketing approval
Other countries: approvals and orphan designations reported by the ex-US licensee
United Kingdom, Canada, and Australia: marketing authorisation
No evidence found.
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Day One Biopharmaceuticals
Nonproprietary name, brand name, and US labeler
Therapeutic class
Origin: acquisition of rights from Takeda
Ex-US licensing agreement with Ipsen
Acquisition of Day One Biopharmaceuticals by Servier
Dosage forms and strengths
United States: tablets and powder for oral suspension
United States: tablet carton configurations by weekly dose
| Weekly dose | Each carton contains | Each blister card contains | NDC |
|---|---|---|---|
| 400 mg | “4 blister cards” | “four 100 mg tablets” | “NDC 82950-001-16” |
| 500 mg | “4 blister cards” | “five 100 mg tablets” | “NDC 82950-001-20” |
| 600 mg | “4 blister cards” | “six 100 mg tablets” | “NDC 82950-001-24” |
United States: oral suspension kit
European Union: film-coated tablets and powder for oral suspension
Average sales price and wholesale acquisition cost
Summary: estimated monthly and annual cost
- Price basis: U.S. wholesale acquisition cost (WAC) as of July 2026 published by Day One Biopharmaceuticals, $41,412.11 per tablet carton (16, 20, or 24 tablets of 100 mg; the same price for all three cartons) and $10,353.03 per single-use oral suspension bottle. Tovorafenib is FDA-approved and marketed for relapsed or refractory BRAF-altered pediatric low-grade glioma; no first-line indication is approved, so this estimate applies the price of the approved product to first-line use.
- Dosing basis: 380 mg/m2 orally once weekly (maximum 600 mg) per the US prescribing information; tablets at 400, 500, or 600 mg once weekly for BSA of 0.90 m2 or more, with each carton holding 4 weekly blister cards; oral suspension at 125 to 600 mg once weekly for BSA of 0.30 m2 or more, with each bottle delivering 300 mg and two bottles reconstituted for doses greater than 300 mg. Treatment continues until disease progression or intolerable toxicity, and the estimate assumes 52 weekly doses per year without interruption.
- Base case: tablets at any BSA of 0.90 m2 or more, $41,412.11 per carton of 4 weekly doses × 13 cartons per year = $538,357 per year; ÷ 12 = $44,863 per month. Oral suspension at 300 mg or less (one bottle per week, BSA 0.30 to 0.83 m2) gives the same cost: $10,353.03 × 52 weeks = $538,358 per year; ÷ 12 = $44,863 per month.
- Range: $538,357 to $1,076,715 per year ($44,863 to $89,726 per month). The upper bound is two oral suspension bottles per week: $20,706.06 × 52 weeks = $1,076,715 per year; ÷ 12 = $89,726 per month.
- Rationale for the range: the flat carton price makes tablet cost independent of the 400, 500, or 600 mg dose and of tablet dose reductions; an oral suspension dose greater than 300 mg requires two single-use bottles, which applies to the 350 mg dose for BSA 0.84 to 0.89 m2 (below the tablet range), to suspension use at BSA of 0.90 m2 or more (375 to 600 mg), and to the second tablet dose reduction for BSA 1.13 to 1.39 m2, which moves to suspension doses of 325 or 375 mg; the suspension dose reductions bring every BSA band of 0.89 m2 or less to 300 mg or less, one bottle per week. Drug holidays and treatment interruptions would lower annual cost and are not modeled.
- Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.
United States: wholesale acquisition cost by package, July 2026
| Package | NDC | WAC price |
|---|---|---|
| Tablets, 16 count | “82950-0001-16” | “$41,412.11” |
| Tablets, 20 count | “82950-0001-20” | “$41,412.11” |
| Tablets, 24 count | “82950-0001-24” | “$41,412.11” |
| Oral suspension, 1 bottle | “82950-0012-01” | “$10,353.03” |
United States: wholesale acquisition cost disclosure terms, July 2026
United States: wholesale acquisition cost by package, January 2025
| Package | NDC | WAC price |
|---|---|---|
| Tablets, 16 count | “82950-0001-16” | “$35,272.64” |
| Oral suspension, 1 bottle | “82950-0012-01” | “$8,818.16” |
United States: wholesale acquisition cost disclosure terms, January 2025
United States: annual launch list price and estimated net price
| Drug | Annual list price | Best annual net price estimate |
|---|---|---|
| Ojemda (tovorafenib) | “$330,720.00” | “$297,648.00” |
United States: dose assumption for the annual price estimate
United States: average sales price
Not applicable.
Prices outside the United States
No evidence found.
American hospital formulary service (AHFS), or other drug classification
AHFS drug class
| Field | Quoted record |
|---|---|
| Brand name | “Ojemda” |
| Drug class | “Antineoplastic Agents” |
Indication
Summary: labeled indications and first-line use
The US and EU labels restrict tovorafenib to relapsed or refractory disease (US) or disease that progressed after one or more prior systemic therapies (EU). Neither label includes first-line (treatment-naive) systemic therapy of pLGG, so first-line use in the US and EU is outside the approved indication until FIREFLY-2 results are reviewed. The Japanese indication statement issued with the September 2026 approval (low-grade glioma with a BRAF gene mutation or fusion gene) does not name a line of therapy, although the supporting data came from FIREFLY-1 in relapsed or progressive disease.
United States: labeled indication, relapsed or refractory pLGG
European Union: labeled indication, pLGG progressed after prior systemic therapy
Japan: approved indication
First-line pLGG: indication under evaluation
Pharmacology
Mechanism of action
Summary: type II RAF inhibition and relevance to BRAF fusion-driven pLGG
Tovorafenib is an oral, CNS-penetrant type II RAF kinase inhibitor of BRAF V600E, wild-type BRAF, and wild-type CRAF, with in vitro IC50 values of 7.1, 10.1, and 0.7 nM, respectively. Type I BRAF inhibitors such as dabrafenib act on monomeric BRAF V600E, do not block signaling from the dimer-dependent KIAA1549:BRAF fusion, and can cause paradoxical MAPK pathway activation in BRAF fusion-driven or BRAF wild-type tumors. Tovorafenib binds RAF monomers and dimers; preclinical studies in pediatric low-grade astrocytoma models showed equipotent activity against BRAF V600E and KIAA1549:BRAF with brain penetrance, and the EMA assessment found no paradoxical activation in BRAF fusion models. Tovorafenib is relatively sparing of ARAF, and in NF1 loss-of-function models without a BRAF alteration it increased ERK phosphorylation at low concentrations, which underlies the NF1-associated tumor warning. The mechanistic data apply to both the approved relapsed or refractory indication and the investigational first-line setting (FIREFLY-2).
Labeled mechanism of action
Binding mode and kinase potency
Rationale for a type II inhibitor in KIAA1549:BRAF fusion tumors
“These drugs (type I antagonists that target the "DFG-in" conformation of the kinase) fail to block signaling via KIAA1549:BRAF, a truncation/fusion BRAF oncoprotein which functions as a dimer and is found in the most common form of PLGA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We identify a type II RAF inhibitor that serves as an equipotent antagonist of BRAFV600E, KIAA1549:BRAF, and other noncanonical BRAF oncoproteins that function as dimers. This drug (MLN2480, also known as TAK-580) has good brain penetrance and is active on authentic human PLGA cells in brain organotypic cultures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Paradoxical MAPK activation: BRAF fusion models versus NF1 loss-of-function models
RAF isoform selectivity: relative ARAF sparing
“We find that tovorafenib and naporafenib are most potent against CRAF but markedly less potent against ARAF.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Type II RAF inhibitors are generally regarded as pan-RAF inhibitors, but our studies of these two agents, together with recent work with type II inhibitors belvarafenib and naporafenib, indicate that relative sparing of ARAF may be a property of multiple drugs of this class.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Exposure-response relationships: US prescribing information
Dose optimization from 420 to 380 mg/m2 based on exposure-response analyses
“There were no clinically significant differences in exposure-response relationships for ORR observed over the actual dose range of 290 to 476 mg/m 2 (0.76-1.25 times the approved recommended dosage) evaluated in Arm 1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on pharmacokinetic/pharmacodynamic modeling, this dose reduction was also anticipated to partially mitigate the reductions in growth velocity observed in children in FIREFLY-1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exposure-safety analyses: EMA assessment
Cardiac electrophysiology
Tumor pharmacodynamic biomarkers: adult melanoma (pERK)
Preclinical activity in pediatric low-grade astrocytoma models
Pharmacokinetics
Summary: pharmacokinetic profile
Based on population PK modelling, tovorafenib at the labeled dose has a steady-state Cmax of 6.9 µg/mL and AUC of 508 µg·h/mL, reaches steady state in 12 days, and has a terminal half-life of approximately 56 hours with no clinically significant accumulation on once-weekly dosing. Median Tmax is 3 hours for tablets and oral suspension; a high-fat meal delays Tmax to 6.5 hours without clinically significant changes in Cmax or AUC. Plasma protein binding is 97.5%. Aldehyde oxidase and CYP2C8 are the primary metabolic enzymes (CYP2C8 fraction metabolized estimated at 49.23% in the PBPK model), and 65% to 66.1% of a radiolabeled dose is recovered in feces and 27% to 28.7% in urine, with less than 0.2% excreted unchanged in urine. In adults (phase 1, 600 mg once weekly), the mean terminal half-life was approximately 70 hours. No formal PK studies were conducted in the pediatric glioma population; exposure was estimated from sparse sampling, and the EMA considered predictions for participants younger than 2 years unreliable (three observations), requiring additional PK data by 30 April 2032. The popPK model estimated 21.5% higher apparent clearance in males than in females.
Pharmacokinetic parameters: US prescribing information
Plasma protein binding and mass balance: EU product information
Population PK model structure and data sources
Covariates: sex, renal function, and hepatic function in the popPK analysis
Pediatric exposure and uncertainty below 2 years of age
Adults with advanced solid tumors: once-weekly pharmacokinetics
“The mean plasma terminal half-life ( t 1/2 ) of tovorafenib was approximately 70 h (range 31–119 h) as defined in 20 evaluable patients receiving 600 mg QW.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For QW dosing regimens, minimum drug accumulation was observed and the geometric mean R auc (accumulation ratio based on AUC 0-last ) was in the range of 1.03–1.09.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Children with relapsed or recurrent MAPK-altered tumors: PNOC014 phase 1
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Summary: labeled warnings and safety profile
All labeled safety data derive from relapsed or refractory disease (FIREFLY-1, 137 participants with pLGG; pooled population of 172 participants including adults with solid tumors at a 600 mg flat dose); the first-line FIREFLY-2 trial is active, not recruiting, with primary completion estimated for June 2027, and no first-line safety results were identified. The US label has no contraindications and no boxed warning; the EU SmPC lists hypersensitivity as the only contraindication. Warnings and precautions cover hemorrhage (37% of the pooled population, including intratumoral hemorrhage in 9% and one fatal tumor hemorrhage), skin toxicity (rash 67%, grade 3 rash 12%; photosensitivity 12%), hepatotoxicity (increased AST 74% and ALT 42%), effect on growth (46% of 133 participants aged 18 years or younger, 35% grade 3 or higher), embryo-fetal toxicity, and possible tumor growth in NF1. In FIREFLY-1, serious adverse reactions occurred in 45% of participants; adverse reactions led to dose interruption in 57%, dose reduction in 24%, and permanent discontinuation in 7%. Growth velocity recovered after treatment stopped in 34 of 38 evaluable participants (89%) in a pooled analysis of three studies. The EU risk management plan lists growth retardation and intratumoral hemorrhage as important identified risks, decreased fertility as an important potential risk, and long-term safety as missing information.
Boxed warning and REMS
No evidence found.
Hemorrhage
Skin toxicity including photosensitivity
Rash incidence, time course, and resolution: FIREFLY-1 post hoc analysis
Hepatotoxicity
Effect on growth: US prescribing information
Effect on growth: proposed mechanism and off-treatment recovery across three studies
Effect on growth: comorbidities in participants with decreased growth velocity
“Overall, 29% had decreased GV from baseline (BL); 19% had ≥50% decrease. Of the 40 with this AESI, 75% had pre-existing neuromuscular or endocrine comorbidities potentially affecting normal growth, including 6 on GnRH-analogues for precocious puberty and 9 with BL heights 2 SDs above/below average for age and sex.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect on growth: PNOC014 phase 1
NF1-associated tumors
Relapsed or refractory pLGG: serious adverse reactions, dose modifications, and discontinuations in FIREFLY-1
Relapsed or refractory pLGG: adverse reactions in 20% or more of participants in FIREFLY-1 (N=137)
| Adverse reaction | All grades (%) | Grade 3 or 4 (%) |
|---|---|---|
| Rash | “77” | “12” |
| Hair color changes | “76” | “0” |
| Fatigue | “55” | “4” |
| Viral infection | “55” | “7” |
| Vomiting | “50” | “4” |
| Headache | “45” | “1” |
| Hemorrhage | “42” | “5” |
| Pyrexia | “39” | “4” |
| Dry skin | “36” | “0” |
| Constipation | “33” | “0” |
| Nausea | “33” | “0” |
| Dermatitis acneiform | “31” | “1” |
| Upper respiratory tract infection | “31” | “1.5” |
| Abdominal pain | “28” | “0” |
| Pruritus | “26” | “1” |
| Edema | “26” | “0” |
| Paronychia | “26” | “1.5” |
| Diarrhea | “22” | “1.5” |
| Stomatitis | “20” | “0” |
Relapsed or refractory pLGG: laboratory abnormalities worsening from baseline in 20% or more of participants in FIREFLY-1
| Laboratory abnormality | All grades (%) | Grade 3 or 4 (%) |
|---|---|---|
| Decreased hemoglobin | “90” | “15” |
| Decreased phosphate | “87” | “25” |
| Increased AST | “83” | “2” |
| Increased creatine phosphokinase | “83” | “11” |
| Increased LDH | “73” | “0” |
| Decreased potassium | “51” | “2” |
| Decreased lymphocytes | “50” | “2” |
| Increased ALT | “50” | “5” |
| Decreased leukocytes | “31” | “2” |
| Decreased albumin | “24” | “5” |
| Increased lymphocytes | “23” | “0” |
| Increased bilirubin | “22” | “1” |
| Decreased sodium | “20” | “2” |
Creatine phosphokinase elevation and anemia: EU product information
Adverse events not observed in FIREFLY-1
“No signs of ocular toxicity, adverse impact on cardiac function or abnormal weight gain were observed in children treated with tovorafenib, unlike those observed with MEK inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although skin rashes were common in children treated with tovorafenib, no patients experienced life-threatening skin reactions, and development of squamous cell carcinomas and keratoacanthomas were not observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EU risk management plan safety concerns
| Category | Quoted safety concern |
|---|---|
| Important identified risks | “Growth retardation” |
| Important identified risks | “Intratumoral haemorrhage” |
| Important potential risks | “Decreased fertility risk” |
| Missing information | “Long-term safety” |
FDA postmarketing requirements related to safety
First-line pLGG: safety results from FIREFLY-2
No evidence found.
Hemorrhage incidence and MAPK inhibitor exposure in a retrospective pediatric low-grade glioma cohort
“Twelve patients (5.1%) experienced hemorrhage over 2,234 person-years (incidence: 0.54/100 person-years). Hemorrhage typically occurred years after initial tumor diagnosis (median 6.4 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MAPK inhibitor exposure was associated with increased hemorrhage risk (HR 4.70, 95% CI 1.36–16.28, p = 0.015)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“tovorafenib showed a high hemorrhage rate (3/4 patients, 75.0%; p = 0.0004, OR 74.33)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The observation is hypothesis-generating and supports prospective monitoring in clinical trials but does not establish causality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bone age, skeletal, and growth hormone findings in participants with decreased growth velocity
Special populations
Pediatric use and age limits
First-line pLGG: age range in FIREFLY-2
Hepatic impairment
Pregnancy
Females and males of reproductive potential: pregnancy testing and contraception
Neurofibromatosis type 1
Geriatric use
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on Tovorafenib
Strong or moderate CYP2C8 inhibitors and inducers: US prescribing information
Examples of CYP2C8 modulators: EU product information
Evidentiary basis: no clinical DDI studies and ongoing gemfibrozil and carbamazepine study
Anticoagulants and antiplatelet agents: hemorrhage risk
Drug-disease interaction: NF1 loss of function
Gastric acid-reducing agents
No evidence found.
Effects of Tovorafenib on other drugs
CYP3A substrates and hormonal contraceptives: US prescribing information
Model-predicted effect on midazolam and in vitro enzyme and transporter effects
Narrow therapeutic index CYP3A substrates, other CYP substrates, and transporter substrates: EU product information
Dosing and administration
Dosage
Summary: dosing regimen and population context
The approved US and EU dose is 380 mg/m2 orally once weekly (maximum 600 mg), with the 100 mg tablet used for BSA of 0.90 m2 or more and the 25 mg/mL oral suspension for BSA of 0.30 to 0.89 m2; no dose is established for BSA below 0.3 m2. Treatment continues until disease progression or intolerable toxicity (EU: also loss of clinical benefit). The approved dose is lower than the 420 mg/m2 dose studied in PNOC014, FIREFLY-1 (actual range 290 to 476 mg/m2), and the first-line FIREFLY-2 trial; FDA selected 380 mg/m2 because exposure-response analyses showed no clinically significant relationship with response across the studied range, while higher exposure was associated with rash, liver enzyme elevation, and creatine phosphokinase elevation. The approved indications concern relapsed or refractory disease; no first-line dosing recommendation exists outside FIREFLY-2.
Recommended dosage: US prescribing information
Tablet dosing by body surface area
| BSA (m2) | Recommended dosage |
|---|---|
| 0.30-0.89 | “Administer OJEMDA oral suspension once weekly” |
| 0.90-1.12 | “400 mg once weekly” |
| 1.13-1.39 | “500 mg once weekly” |
| 1.40 or more | “600 mg once weekly” |
Oral suspension (25 mg/mL) dosing by body surface area
| BSA (m2) | Dose volume (mL) | Dosage |
|---|---|---|
| 0.30-0.35 | “5” | “125 mg once weekly” |
| 0.36-0.42 | “6” | “150 mg once weekly” |
| 0.43-0.48 | “7” | “175 mg once weekly” |
| 0.49-0.54 | “8” | “200 mg once weekly” |
| 0.55-0.63 | “9” | “225 mg once weekly” |
| 0.64-0.77 | “11” | “275 mg once weekly” |
| 0.78-0.83 | “12” | “300 mg once weekly” |
| 0.84-0.89 | “14” | “350 mg once weekly” |
| 0.90-1.05 | “15” | “375 mg once weekly” |
| 1.06-1.25 | “18” | “450 mg once weekly” |
| 1.26-1.39 | “21” | “525 mg once weekly” |
| 1.40 or more | “24” | “600 mg once weekly” |
Dose reductions for adverse reactions: tablets
| BSA (m2) | First dosage reduction | Second dosage reduction |
|---|---|---|
| 1.13-1.39 | “400 mg once weekly” | “Administer OJEMDA oral suspension once weekly” |
| 1.40 or more | “500 mg once weekly” | “400 mg once weekly” |
Dose reductions for adverse reactions: oral suspension
| BSA (m2) | First reduction volume (mL) | First reduction dose | Second reduction volume (mL) | Second reduction dose |
|---|---|---|---|---|
| 0.30-0.35 | “4” | “100 mg once weekly” | “3” | “75 mg once weekly” |
| 0.36-0.42 | “5” | “125 mg once weekly” | “4” | “100 mg once weekly” |
| 0.43-0.48 | “6” | “150 mg once weekly” | “5” | “125 mg once weekly” |
| 0.49-0.54 | “7” | “175 mg once weekly” | “6” | “150 mg once weekly” |
| 0.55-0.63 | “8” | “200 mg once weekly” | “6” | “150 mg once weekly” |
| 0.64-0.77 | “9” | “225 mg once weekly” | “8” | “200 mg once weekly” |
| 0.78-0.83 | “10” | “250 mg once weekly” | “8” | “200 mg once weekly” |
| 0.84-0.89 | “12” | “300 mg once weekly” | “10” | “250 mg once weekly” |
| 0.90-1.05 | “13” | “325 mg once weekly” | “11” | “275 mg once weekly” |
| 1.06-1.25 | “15” | “375 mg once weekly” | “13” | “325 mg once weekly” |
| 1.26-1.39 | “18” | “450 mg once weekly” | “15” | “375 mg once weekly” |
| 1.40 or more | “20” | “500 mg once weekly” | “16” | “400 mg once weekly” |
Dosage modifications by adverse reaction
| Adverse reaction and severity | Quoted modification |
|---|---|
| Hemorrhage, intolerable grade 2 or any grade 3 | “If improved to Grade 0-1, resume at lower dosage.” |
| Hemorrhage, recurrent grade 4 | “Permanently discontinue OJEMDA.” |
| Hepatotoxicity, grade 3 AST, ALT, or bilirubin | “If laboratory abnormality resolves within 8 days, resume OJEMDA at the same dose.” |
| Hepatotoxicity, grade 3 AST, ALT, or bilirubin | “If laboratory abnormality does not resolve within 8 days, resume OJEMDA at lower dosage.” |
Testing before initiation
Recommended dose and duration: EU product information
Relapsed or refractory pLGG: dose studied in FIREFLY-1 and optional drug holiday
Rationale for the approved dose lower than the phase 2 dose
“As greater tovorafenib exposure is associated with increased risk of Grade ≥2 adverse events including skin rash, elevated liver enzymes, and elevated creatine phosphokinase, a modest reduction from 420 to 380 mg/m 2 was recommended to optimize the dose and improve the benefit-to-risk ratio in pediatric patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommended phase 2 dose: PNOC014
First-line pLGG: dosing in FIREFLY-2
“Dosage is adjusted for body surface area (BSA) calculated per the Mösteller Formula [√((height × weight)/3600)].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upon resolution and/or reversion, dosing may be restarted at the same dose or a lower dose, at the discretion of the local investigator.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration
Schedule, food, missed doses, and vomiting
Minimum interval between doses: EU product information
Oral suspension: reconstitution, feeding tube use, and time limit
Formulation interchangeability and supervision: EU product information
First-line pLGG: formulation use in FIREFLY-2
“in the form of a tablet or liquid suspension, QW, continuously on days 1, 8, 15, and 22 of 28-day (four week) cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“patients randomized to tovorafenib will receive an oral drug that is taken at home once weekly, that is available in both tablet and a pediatric friendly oral suspension that can be also given via a nasogastric or gastric tube, allowing continuation of daily activities such as attending school.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Access and distribution
United States: specialty pharmacy distribution
United States: manufacturer patient support program
United States: copay assistance and free drug program
United States: manufacturer-reported coverage approval rate and time to receipt
United States: payer prior authorization criteria limited to relapsed or refractory disease
United States: Risk Evaluation and Mitigation Strategy
European Union: prescription status, Joint Clinical Assessment, and launch
Japan: companion diagnostic approval
First-line pLGG: access outside clinical trials
No evidence found.
NCCN Guidelines listing
No evidence found.
Co-prescribed/Concomitant therapies
Summary: supportive care during tovorafenib treatment
Labeled supportive measures comprise ultraviolet protection (sunscreen, sunglasses, protective clothing; the EU SmPC specifies SPF 50 or higher), dermatologic consultation and supportive care for skin reactions, liver function monitoring before treatment, at 1 month, and every 3 months, routine growth monitoring, and effective nonhormonal contraception. In FIREFLY-1 (relapsed or refractory pLGG), the protocol recommended a gentle skin care routine with thick unscented moisturizers and SPF 30 or higher sunscreen for all participants, and 102 of 128 participants with rash (80%) received standard rash treatments, primarily topical steroids or antibiotics, oral antihistamines, and emollients. In a pooled growth analysis of 38 participants, 4 (11%) received a gonadotropin-releasing hormone analogue and 2 (5%) received growth hormone concurrently with tovorafenib. No published supportive care guideline specific to first-line tovorafenib use was identified.
Sun protection: US prescribing information
Relapsed or refractory pLGG: protocol skin care and rash management in FIREFLY-1
“It was recommended that all trial patients followed a gentle skin care routine comprising short lukewarm showers/baths, the use of unscented, gentle cleansers and the application of unscented thick moisturizers (creams over lotions) immediately after showers. In addition, the prophylactic use of SPF 30+ sunscreen whenever going outside, with this reapplied every 2 h, and the wearing of sun-protective clothing were recommended for all patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were to be referred to a dermatology department if cutaneous symptoms were impairing function (for example, if the patient could not sleep or sit still) or were psychosocially bothersome and/or when management techniques failed to resolve the condition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Relapsed or refractory pLGG: rash treatments used in FIREFLY-1
Growth and endocrine monitoring
“Normative data for growth in this patient population are lacking, and future studies of targeted therapies in pLGG should include baseline and longitudinal assessments of endocrine function and monitoring of growth velocity during therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concomitant endocrine therapies in treated participants
First-line pLGG: safety monitoring in FIREFLY-2
“In addition to standard ophthalmology examination, monitoring for safety will include physical examination, neurologic examination, dermatology examination, cardiac evaluation, bone assessment (for patients with Tanner stage < 4–5), Karnofsky/Lansky performance score, clinical AEs, laboratory variables and vital signs, including height and weight.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antiemetic prophylaxis and premedication
No evidence found.
Effect of Tovorafenib on quality measures
Product-specific effect on quality measures
No evidence found.
Quality measures for pediatric low-grade glioma or pediatric CNS tumor care that reference targeted therapy
No evidence found.
Product comparison
Summary: comparative evidence for tovorafenib versus other systemic options
No randomized comparison of tovorafenib with any other therapy has been reported as of September 2026. The phase 3 LOGGIC/FIREFLY-2 trial, which compares tovorafenib with investigator's choice of standard chemotherapy in first-line RAF-altered pLGG, completed enrollment of approximately 400 participants in May 2026, with preliminary results expected in 2027. The only formal indirect comparison identified is the EU Joint Clinical Assessment (JCA) of tovorafenib in relapsed or refractory pLGG, endorsed on 30 April 2026. Of 8 PICO questions, the developer submitted comparative data for 2 (PICO 5 and PICO 7), and the assessors included 1: an unanchored matching-adjusted indirect comparison (MAIC) of FIREFLY-1 against a phase I/II dabrafenib plus trametinib study in the BRAF V600E subpopulation. The effective sample size was 5.81 to 14.26. For independent review committee (IRC)-assessed progression-free survival (PFS) by RANO-LGG, the hazard ratio was 4.88 (95% CI 2.14 to 11.14; nominal p = 0.011), a direction unfavorable to tovorafenib; objective response comparisons were inconclusive; and the odds ratio for grade 3 or higher adverse events was 12.65 (95% CI 2.30 to 69.58). The assessors stated that these estimates "should not necessarily be interpreted as causal effects of treatment." The comparison with trametinib (TRAM-01) was excluded because the comparator was reported only in conference abstracts.
Independent reviews published in 2025 and 2026 compare agents on mechanism and indication rather than head-to-head efficacy. Type I BRAF inhibitors (dabrafenib, vemurafenib) are restricted to BRAF V600-mutant tumors because of paradoxical MAPK activation in BRAF fusion-driven tumors, whereas tovorafenib is active in both fusion and V600 tumors. Reviewers describe once-weekly dosing without food restrictions and an available oral suspension for tovorafenib, compared with once- or twice-daily dosing for MEK and BRAF inhibitors. Reviewers also describe differences in adverse event profiles: reduced growth velocity has been reported only with tovorafenib, and intratumoral hemorrhage was reported in 9% of the pooled pediatric tovorafenib safety population, while pyrexia is more frequent with dabrafenib plus trametinib and cardiac and ocular monitoring is emphasized for MEK inhibitors. A 2026 systematic review found rebound regrowth after MAPK inhibitor discontinuation in at least 23 of 131 evaluable participants (17.6%) and 1 rebound event among 24 evaluable FIREFLY-1 participants who entered a drug holiday, while noting short post-discontinuation follow-up.
Direct randomized comparisons: status of LOGGIC/FIREFLY-2
EU joint clinical assessment: comparators and data submitted per PICO
| Population and PICO | Comparator | Results submitted | Data included in the JCA report |
|---|---|---|---|
| Population 1 (full claimed indication), PICO 3 | “Combination of carboplatin and vincristine” | “no” | “no” |
| Population 1 (full claimed indication), PICO 4 | “Vinblastine” | “no” | “no” |
| Population 2 (BRAF V600E mutation in patients > 1 year), PICO 5 | “Combination of dabrafenib and trametinib” | “yes” | “yes” |
| Population 3 (BRAF fusion, rearrangement, or V600 [non-E] mutation), PICO 7 | “Trametinib” | “yes” | “no” |
Relapsed or refractory BRAF V600E pLGG: unanchored MAIC versus dabrafenib plus trametinib, efficacy
| Outcome | Tovorafenib (FIREFLY-1) | Dabrafenib plus trametinib (Bouffet 2023) | ESS | Relative effect |
|---|---|---|---|---|
| 6-month PFS, RANO-LGG, IRC | “94 [85, 100]” | “86 [75, 98]” | “5.81” | “RR: 1.09 [0.92; 1.30]” |
| 12-month PFS, RANO-LGG, IRC | “76 [52, 100]” | “83 [71, 96]” | “5.81” | “RR: 0.92 [0.61, 1.38]” |
| CR+PR by RANO-HGG, investigator | “40.0 [12.2, 73.8]” | “52.8 [NR, NR]” | “6.64” | “OR: 0.56 [0.08, 3.84]” |
| CR+PR by RANO-HGG, IRC | “50.0 [18.7, 81.3]” | “19.4 [8.2, 36.0]” | “6.64” | “OR: 7.26 [0.98, 53.68]” |
| PFS by RANO-LGG, IRC, median months | “13.67 [4.60, 24.87]” | “36.9 [36.0, NE]” | “5.81” | “4.88 [2.14, 11.14]” |
Relapsed or refractory BRAF V600E pLGG: unanchored MAIC versus dabrafenib plus trametinib, safety
| Outcome | Tovorafenib (FIREFLY-1) | Dabrafenib plus trametinib (Bouffet 2023) | ESS | Odds ratio [95% CI] |
|---|---|---|---|---|
| Severe AE (CTCAE grade 3 or higher) | “20 (22)” | “22 (36)” | “14.26” | “12.65 [2.30, 69.58]” |
| Serious AE | “13 (22)” | “15 (36)” | “14.26” | “3.04 [0.77, 12.10]” |
| Treatment interruption due to AE | “15 (22)” | “26 (36)” | “14.26” | “1.15 [0.28, 4.76]” |
| Treatment discontinuation due to AE | “3 (22)” | “8 (36)” | “14.26” | “0.58 [0.11, 3.03]” |
| Death related to AE | “2 (22)” | “0 (36)” | Not reported | “NA: Indirect comparison not provided due to zero event rate in dabrafenib + trametinib group” |
EU joint clinical assessment: uncertainties of the indirect comparison
EU joint clinical assessment: comparison with trametinib not assessed
Independent commentary on the joint clinical assessment findings
“Overall survival could not be estimated at all. The only outcome reaching nominal statistical significance was progression-free survival, and it favored the comparator. Objective response was inconclusive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the descriptive safety data, tovorafenib showed numerically more serious and severe adverse events than the comparator.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Yet the limitations are so pervasive – small numbers, an unanchored comparison – that the report cannot conclude the drug is inferior.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mechanism-based selection: type II RAF inhibitor versus type I BRAF inhibitors
“BRAF targeted therapy should be selected in a mutation-specific fashion. Type 1 BRAFi (i.e., dabrafenib) are not effective against BRAF fusions and can result in paradoxical activation and tumor progression. Tovorafenib is effective in recurrent pLGG with BRAFV600 or BRAF fusions, while dabrafenib is ineffective in tumors with BRAF fusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Type I RAF inhibitors such as dabrafenib are not indicated for the treatment of tumors harboring a BRAF fusion due to paradoxical activation which may increase the risk of tumor growth (10). Prior to the approval of tovorafenib, there were no approved targeted therapies for patients with pLGG harboring BRAF fusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Review table: regulatory status and key considerations by agent
Review table: evidence in pLGG by agent
Adverse event profiles across MAPK inhibitor classes
“The common acute adverse effects of the type II RAF inhibitor tovorafenib included hair color change (Figure 2E), anemia, elevated creatine kinase, and cutaneous reactions. Importantly, a reversible decrease in growth velocity (Figure 2F), and an increased incidence of intra-tumoral hemorrhage were reported. Pyrexia, diarrhea, and weight gain were reported to be less common than MEK/BRAF inhibitors, and no signs of ocular and cardiac toxicity were reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While most toxicities of MAPKi therapies are thought to be a direct effect of MAPKi inhibition, type I BRAFi are selective mutant inhibitors, which can proceed to paradoxical activation of the MAPK pathway resulting in secondary skin malignancy;27,28 this is not seen with type II RAFi and MEKi.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, reductions in growth velocity have only been observed in patients with pLGG treated with tovorafenib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interestingly, tovorafenib can lead to growth arrest – a side effect that hasn’t been reported with any of the MEK inhibitors, and it is unknown whether this particular toxicity is considered a class effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intracranial hemorrhage across MAPK inhibitors
“In the phase 2 FIREFLY-1 trial of tovorafenib in BRAF-altered pLGG (n = 137), any-site hemorrhage of any grade occurred in 42% of patients with grade 3-4 hemorrhage in 7 patients (5%) and, separately, one fatal grade 5 intratumoral hemorrhage; in the overlapping pooled FDA-label safety population (N = 140), intratumoral hemorrhage specifically was reported in 9%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reported incidence varies by agent, population, and hemorrhage ascertainment method (active imaging-based surveillance versus clinical reporting), from < 1% symptomatic ICH with dabrafenib in adult melanoma to 9% intratumoral hemorrhage in the pooled pediatric tovorafenib safety population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The presence of a KIAA1549::BRAF fusion in the tumor had the strongest association with hemorrhage, persisting across multivariable models (approximately sixfold increased risk), although estimates were limited by low event number. MAPK inhibitor exposure (specifically binimetinib and tovorafenib) was associated with hemorrhage in univariate analysis but partially confounded by fusion status.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dosing schedule, formulation, and route compared with other agents
“The availability of a liquid formulation, a weekly dosing regimen (in contrast to daily doses for other available BRAF/MEK inhibitors) and lack of food effect, may make drug compliance easier for young patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on pharmacokinetic studies, MEK and BRAF inhibitors are given daily (once to twice per day), with some MEK inhibitors requiring an empty stomach for optimal absorbtion (45, 55). Tovorafenib can be taken with or without food and is administered once weekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rebound regrowth after discontinuation: pan-RAF inhibitor versus earlier agents
“it seems that the incidence of RR following pan-RAF inhibitors may be lower compared to earlier generation drugs, although these findings should be interpreted with caution given the relatively short post-discontinuation follow-up (range: 0.6–10.9 months), limiting detection of delayed events (30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Targeted therapy versus chemotherapy in BRAF V600-mutant pLGG: meta-analysis
“Ten studies (16 treatment arms; 4 RCTs, 6 RS were included). Pooled ORR was 42.35% (95% CI, 29.41-55.29), and the median PFS was 23.03 months (95% CI, 17.18-28.88). Grade 3/4 AEs occurred in 30.56% (95% CI, 22.60-38.53), most commonly rash, fatigue, and fever. Subgroup analyses suggested higher efficacy and lower toxicity with BRAF inhibitors or combination therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Emerging evidence suggests potential benefit in selected molecularly defined patients; however, further prospective studies are required to define their role in first-line treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of first-line dabrafenib plus trametinib versus chemotherapy
“Dab-Tram was associated with a 2.21 quality-adjusted life-year (QALY) gain at an incremental cost of $554,769 Canadian dollars (CAD) compared with standard chemotherapy. The base case incremental cost-effectiveness ratio (ICER) was $251,027 CAD/QALY. Two-year Dab-Tram resulted in an ICER of $44,740 CAD/QALY” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Weight gain with dabrafenib plus trametinib in first-line pediatric low-grade glioma
“However, weight gain as an adverse event or an increase of at least 2 BMI-for-age percentiles was reported in 32 of 73 patients who received dabrafenib plus trametinib.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our analysis suggests that tumor location does not appear to be associated with the weight gain observed with dabrafenib plus trametinib, findings that support other reports that suggest weight gain as a safety signal with MAPK-targeted therapy in this patient population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Any-grade adverse events and reasons for dose modification with dabrafenib plus trametinib compared with carboplatin and vincristine
“Overall, 106 patients were included in the safety analysis (73 for dabrafenib plus trametinib and 33 for chemotherapy).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common adverse events of any grade with dabrafenib plus trametinib as compared with chemotherapy were pyrexia (in 68% vs. 18%), headache (in 47% vs. 27%), and vomiting (in 34% vs. 48%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among the patients who received dabrafenib plus trametinib, dose adjustments or interruptions were more frequent because of pyrexia (in 53% vs. 0 with chemotherapy) and were less frequent because of a decreased neutrophil count (in 3% vs. 27% with chemotherapy).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although skin toxic effects (including dry skin and rash) occurred more frequently with dabrafenib plus trametinib, only 8% of patients had resultant dose interruption or adjustment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Progression events by independent versus investigator assessment in the comparator trial
“A discrepancy in progression events was noted between independent and investigator assessments in the two trial groups (30 vs. 9 events with dabrafenib plus trametinib and 22 vs. 9 with chemotherapy).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Strict interpretation of the RANO criteria by the independent reviewer may have contributed to the higher number of progression events reported as compared with investigator review, because the criteria for progressive disease are sensitive to increases relative to nadir, regardless of changes from baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hemorrhage rates by individual MAPK pathway inhibitor
“Binimetinib showed a particularly strong association (3/17 patients, 17.6%; HR 6.24, 95% CI 1.55–25.11, p = 0.010, OR 5.00)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Selumetinib (0/11), trametinib (1/9, 11.1%), and dabrafenib (0/6) showed no significant associations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cytotoxic chemotherapy, radiation, and other systemic therapies (including anti-angiogenic agents) were not associated with increased hemorrhage risk.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EU joint clinical assessment: failed attempt to construct external control arms for the comparisons without trial data
Germany: orphan drug rule restricting the benefit assessment to patient numbers and costs
Place of product in therapy
Disease description
Definition and etiology
Summary: definition and molecular etiology
Pediatric low-grade glioma (pLGG) is a heterogeneous group of WHO CNS grade 1 and 2 glial, glioneuronal, and neuronal tumors that account for 30% to 40% of pediatric CNS tumors. The 2021 fifth edition of the WHO classification (WHO CNS5) distributes these tumors across three families: pediatric-type diffuse low-grade gliomas (4 types, including diffuse low-grade glioma, MAPK pathway-altered), circumscribed astrocytic gliomas (including pilocytic astrocytoma, the most common type), and glioneuronal and neuronal tumors. Diagnosis is integrated and layered, combining histology with molecular findings.
The disease is driven predominantly by alterations that activate the RAS/MAPK pathway. In a population-based cohort from Toronto with molecular profiling of 477 tumors, a driver alteration was identified in 84%; KIAA1549-BRAF fusion was the most frequent alteration (35%), followed by BRAF p.V600E (17%), with germline NF1, FGFR1/2 (6.1%), and rare RAF1, NTRK2, ALK, and ROS1 alterations accounting for most of the remainder. Whole-genome sequencing of 96 pilocytic astrocytomas found MAPK pathway alterations in 100%. Germline NF1 is the main hereditary predisposition, with 15% to 20% of children with NF1 developing an optic pathway glioma.
Definition: pLGG as WHO grade 1 and 2 tumors, the most common childhood CNS tumor
“pLGG comprises 30%–40% of all pediatric CNS tumors, including a heterogeneous group of World Health Organization (WHO) grades 1 and 2 glioma, glioneuronal and neuronal neoplasms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tumors that have historically been classified as pLGG now fall under several subcategories within the 2021 WHO glioma, glioneuronal, and neuronal tumor sections, including pediatric-type diffuse low-grade glioma, circumscribed astrocytic tumors, and glioneuronal and neuronal tumors (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, the most common type of pLGG, the pilocytic astrocytoma, remains a distinct entity, but it is now characterized as a type of circumscribed astrocytic tumor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
WHO CNS5 (2021): pediatric-type diffuse low-grade gliomas and circumscribed astrocytic gliomas
“WHO CNS5 has taken a new approach to classify the Gliomas, Glioneuronal Tumors, and Neuronal Tumors, and dividing them into 6 different families: (1) Adult-type diffuse gliomas (the majority of primary brain tumors in neuro-oncology practice of adults, eg, glioblastoma, IDH-wildtype); (2) Pediatric-type diffuse low-grade gliomas (expected to have good prognoses)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For CNS5, the 4 types are Diffuse astrocytoma, MYB- or MYBL1-altered; Angiocentric glioma; Polymorphous low-grade neuroepithelial tumor of the young (often abbreviated as PLNTY; Figure 1); and Diffuse low-grade glioma, MAPK pathway-altered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For these tumors (as for most other glioma types), precise classification requires molecular characterization and the integration of histopathological and molecular information in a tiered diagnostic format. Clear delineation of the specific molecular features, in turn, sets the stage for targeted therapies of such tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two specific aspects of CNS tumor grading have changed for WHO CNS5: Arabic numerals are employed (rather than Roman numerals) and neoplasms are graded within types (rather than across different tumor types).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
WHO CNS5 (2021): key diagnostic genes for tumor types within the pLGG spectrum
| Tumor type | Key diagnostic genes, molecules, pathways, or combinations |
|---|---|
| Pilocytic astrocytoma | “KIAA1549-BRAF, BRAF, NF1”View highlighted excerpt for this quote |
| Diffuse low-grade glioma, MAPK pathway-altered | “FGFR1, BRAF”View highlighted excerpt for this quote |
| Polymorphous low-grade neuroepithelial tumor of the young | “BRAF, FGFR family”View highlighted excerpt for this quote |
| Pleomorphic xanthoastrocytoma | “BRAF, CDKN2A/B”View highlighted excerpt for this quote |
| Diffuse astrocytoma, MYB- or MYBL1-altered | “MYB, MYBL1”View highlighted excerpt for this quote |
| Angiocentric glioma | “MYB”View highlighted excerpt for this quote |
Etiology: RAS/MAPK pathway alterations in a cohort of more than 1,000 pLGG
“84% of cases harbored a driver alteration, while those without an identified alteration also often exhibited up-regulation of the RAS/MAPK pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“KIAA1549-BRAF was the most frequent alteration in pLGG (35%) and was almost exclusively a single-event driver (n=175/180, 97%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BRAF p.V600E was the second most common alteration in pLGG (17%) and was frequently associated with additional alterations, most commonly deletion of CDKN2A (n=13, 9.6%) (Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A further 1.3% (n=6) of cases contained alterations in other direct members of the RAS/MAPK pathway, including 3 RAF1 fusions, 2 KRAS mutations and one patient with a short deletion in MAP2K1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Alterations in FGFR most frequently involved FGFR1/2 (n=29, 6.1%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“as well as fusions involving ALK (n=2, 0.4%), ROS1 (n=2, 0.4%), and NTRK2 (n=2, 0.4%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In our study, NF1-driven pLGG accounted for 14% of cases (n=133).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: KIAA1549::BRAF fusion from tandem duplication at 7q34
“This rearrangement, which was not observed in a series of 244 higher-grade astrocytomas, results in an in-frame fusion gene incorporating the kinase domain of the BRAF oncogene. We further show that the resulting fusion protein has constitutive BRAF kinase activity, and is able to transform NIH3T3 cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“KIAA1549-BRAF accounts for 30-40% of pLGG at the population level” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: BRAF V600E frequency across histologies and locations
“BRAF V600E mutation was detected in 69 of 405 patients (17%) with PLGG across a broad spectrum of histologies and sites, including midline locations, which are not often routinely biopsied in clinical practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As expected, the highest incidence of the mutation was observed in pleomorphic xanthoastrocytoma (78%) followed by gangliogliomas (49%); however, the mutation was also commonly observed in diffuse astrocytomas (43%) and WHO grade I astrocytomas (20%; Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 33% of BRAF V600E PLGGs originated in the midline (diencephalon and brainstem).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: pilocytic astrocytoma as a single-pathway disease; FGFR1 and NTRK2 alterations
“We identified recurrent activating mutations in FGFR1 and PTPN11 and novel NTRK2 fusion genes in non-cerebellar tumors. New BRAF activating changes were also observed. MAPK pathway alterations affected 100% of tumors analyzed, with no other significant mutations, indicating pilocytic astrocytoma as predominantly a single-pathway disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: neurofibromatosis type 1 as the principal predisposition syndrome
“10-15% of children with NF1 will develop a low-grade glioma within the optic pathway, with an additional 3-5% arising outside of the optic pathway” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with NF1 account for over 70% of the optic pathway/hypothalamic gliomas in children, and it is estimated that 15%–20% of all children with NF1 will develop an optic pathway glioma (OPG) during early childhood.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company description of RAF alteration frequency
Epidemiology
Incidence of RAF-altered pediatric low-grade glioma requiring first-line systemic therapy
Summary: incidence estimates and the population requiring first-line systemic therapy
No identified publication reports the incidence of RAF-altered pLGG requiring first-line systemic therapy directly. The available components are as follows.
- Overall incidence, United States: the CBTRUS childhood and adolescent report (2017 to 2021 diagnoses) reports an annual incidence of 0.98 per 100,000 for pilocytic astrocytoma in ages 0 to 19 years and projects 730 new pilocytic astrocytoma cases in 2025. The LOGGIC/FIREFLY-2 design publication cites 1,200 to 1,500 new pLGG cases per year in the United States. Day One Biopharmaceuticals cites an annual incidence of 1.3 to 2.1 per 100,000.
- Overall incidence, Europe: in Great Britain, the incidence of pilocytic astrocytoma at ages 0 to 14 years was 8.6 per million in 2006 to 2010.
- RAF-altered fraction: KIAA1549-BRAF fusion was found in 35% and BRAF p.V600E in 17% of profiled tumors in a population-based Toronto cohort. Day One Biopharmaceuticals estimates that approximately 1,100 patients under 25 years of age are newly diagnosed with BRAF-altered pLGG in the United States each year.
- Fraction requiring nonsurgical therapy: in the UK CCLG CNS9702 population-based cohort, 165 of 639 children (25.8%) started nonsurgical treatment at diagnosis (113 chemotherapy, 52 radiotherapy). In the German HIT-LGG-1996 cohort of 1,031 children, 184 proceeded to nonsurgical treatment at diagnosis and 35.2% ultimately received nonsurgical treatment. In SIOP-LGG 2004, 1,057 of 3,417 registered, previously untreated patients (30.9%) received chemotherapy. Reviews state that up to half of patients require adjuvant therapy.
United States: CBTRUS incidence of pilocytic astrocytoma and glioma in ages 0 to 19 years
“Among CBTRUS specific histopathology groupings, incidence rates were highest for pilocytic astrocytoma (0.98 per 100,000) and tumors of the pituitary (0.98 per 100,000).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequently reported histopathology in all ages (0-19 years) was pilocytic astrocytoma (16.3%). Overall, gliomas accounted for 45% of all brain tumors diagnosed in ages 0-19 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pilocytic astrocytoma and tumors of the pituitary had the highest number of estimated new cases, with 730 new cases per histopathology expected to be diagnosed in 2025.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median age of glioma diagnosis was 9 years with subtypes ranging from 7 years for pilocytic astrocytoma to 11 years for other low-grade glioma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In children ages 0-3 years, pilocytic astrocytoma tumors had a significant increase in incidence during the entire period (APC: 3.0%; 2.1%, 3.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: registry coding change for pilocytic astrocytoma from 2023
“It should be noted that cases of pilocytic astrocytoma or juvenile pilocytic astrocytoma diagnosed in, or after, 2023 (and therefore not available for analysis until 2026) will no longer be considered malignant (/3), but uncertain (/1); ICD-O-3 code 9421/3 will be reserved for high grade astrocytoma with piloid features.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: annual number of new pLGG cases
“Pediatric low-grade glioma (pLGG) is a heterogeneous group of World Health Organization (WHO) grade 1 and 2 tumors comprising several subgroups and is the most frequent pediatric central nervous system (CNS) tumor diagnosis, with 1200 to 1500 new cases per year in the United States (US)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: company estimates of pLGG and BRAF-altered pLGG incidence
Europe: population-based incidence of pilocytic astrocytoma in Great Britain
“Age-standardised incidence in 2001–10 was 40.1 per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Between the same two periods, the proportional increase was greater for pilocytic astrocytoma (202%, from 2.9 per million to 8.6 per million) than for astrocytomas of other or unspecified subtype (40%, from 5.8 per million to 8.2 per million)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent single histological type of tumour was pilocytic astrocytoma, which accounted for one half of all astrocytomas and 21% of all tumours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The highest incidence of pilocytic astrocytoma and unspecified optic nerve astrocytoma was at age 1–4 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Europe: proportion of children starting nonsurgical therapy in the UK population-based CNS9702 cohort
“This network registered 80%–86% of the UK cases of childhood LGG registered by the national childhood cancer registry during this time period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Four hundred and seventy-four (74.2%) were initially observed (median age: 7.43 years; Fig. 1). One hundred and sixty-five (25.8%) started nonsurgical treatment (median age: 4.95 years), 113 had chemotherapy (median age: 3.65 years), and 52 had radiotherapy (median age: 9.36 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Europe: proportion of children receiving nonsurgical therapy in the German HIT-LGG-1996 cohort
“Following first surgical intervention in 916 children and radiologic diagnosis in 115 children, 847 patients were observed and 184 proceeded to nonsurgical treatment at diagnosis (1 without exact date).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After initial observation, progression occurred in 40.9% of cases within 10 years and indicated nonsurgical therapy in 51.7%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ultimately, 35.2% of patients in our study received nonsurgical treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Europe: registrations and chemotherapy use in the SIOP-LGG 2004 study
“3417 previously untreated patients from 118 institutions in 11 countries were registered at the SIOP-LGG 2004 database following the SIOP-LGG treatment strategy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the trial period, 1057 patients received chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proportion requiring therapy beyond surgery by tumor location
“However, with progression-free survival (PFS) at approximately 50%, up to half of patients will require adjuvant therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, many pLGGs arise within structures of the brain that cannot be safely resected without causing substantial morbidity, for example, the optic pathway; midline locations involving the hypothalamus, thalamus, or brainstem; or those intricately associated with motor pathways. Tumors in these locations, in addition to those pLGGs with multiply recurrent or metastatic disease, often require therapy beyond surgery with a few exceptions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“hypothalamic-chiasmatic tumours in particular are generally considered unresectable, they present when the children are very young and can threaten vision, endocrine function and require non-surgical therapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Directly measured incidence of RAF-altered pLGG requiring first-line systemic therapy
No evidence found.
Prevalence of RAF-altered pediatric low-grade glioma requiring first-line systemic therapy
Summary: prevalence estimates
No identified publication reports the prevalence of RAF-altered pLGG requiring first-line systemic therapy. CBTRUS projects that 42,864 children and adolescents aged 0 to 19 years in the United States were living with a primary brain or other CNS tumor in 2025, including 21,591 with glioma and 9,193 with pilocytic astrocytoma; these figures exclude survivors who have reached adulthood. Day One Biopharmaceuticals reports a registry-based estimate (SEER and CBTRUS) of 26,000 patients under 25 years of age with BRAF-altered pLGG in the United States as of January 1, 2017, and an addressable pool of 2,000 to 3,000 patients per year with recurrent, progressive, or refractory pLGG at steady state.
United States: CBTRUS prevalence of pilocytic astrocytoma and glioma in ages 0 to 19 years
“An estimated 42,864 children and adolescents ages 0-19 years will be living with a primary brain or other CNS tumor diagnosis in 2025, making it the most prevalent tumor type in the age range.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The histopathologic group with the highest prevalence was gliomas, with 21,591 cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 2025, the most prevalent histopathologic group is expected to be pilocytic astrocytoma (an estimated 9,193 cases).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As these estimates include only children and adolescents 0-19 years of age at time of prevalence estimate, the total population of childhood and adolescent brain tumor survivors including those that are now in adulthood is significantly larger.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: company estimates of BRAF-altered pLGG prevalence and addressable population
Prevalence of RAF-altered pLGG requiring first-line systemic therapy
No evidence found.
Natural history, survival, and mortality
Summary: survival, progression, and mortality
Long-term overall survival in pLGG is high, and tumor-related mortality is uncommon. In 4,040 children in SEER (1973 to 2008), 20-year overall cancer-specific survival was 87% and the 20-year cumulative incidence of death due to glioma was 12%, falling to 7% after age 22 years. In a population-based Ontario cohort of 1,202 children, 93 deaths (7.7%) occurred over a median of 12.73 years, with 20-year overall survival of 90.1%. Upfront radiotherapy was associated with higher late mortality in both cohorts (hazard ratios 3.9 and 3.3).
Progression is frequent among children who need systemic therapy. In COG A9952 (274 randomized children younger than 10 years), 5-year event-free survival was 39% with carboplatin and vincristine and 52% with TPCV, and was 19% in children younger than 1 year. In SIOP-LGG 2004 (497 randomized non-NF1 patients), 5-year progression-free survival was 46% with vincristine and carboplatin and 45% with added etoposide. In HIT-LGG-1996, 10-year progression-free survival after chemotherapy was 44%. Approximately 40% to 50% of children require subsequent chemotherapy lines.
Molecular subtype modifies prognosis. In the Toronto cohort, 5-year progression-free survival was 69% for KIAA1549-BRAF and 52% for BRAF p.V600E tumors. BRAF V600E tumors had 10-year progression-free survival of 27% versus 60.2% for wild-type tumors, and 5-year progression-free survival after first-line chemotherapy of 30.4%. BRAF p.V600E with CDKN2A deletion was associated with 10-year progression-free survival of 0% and 10-year overall survival of 41%. Low-risk tumors (fusions or germline NF1) often stop growing, with few progressions after 10 years. Malignant transformation was observed in fewer than 1% of the HIT-LGG-1996 cohort.
Long-term overall survival and tumor-related death: SEER cohort of 4,040 children
“The 20-year OS was 87% ± 0.8% and the 20-year cumulative incidence of death due to glioma was 12% ± 0.8%. The incidence of death after transition to adulthood (age greater than 22 years) was slightly lower, with 20-year cumulative incidence of disease death of 7% ± 1.8%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 30-year OS of the 4,040 patients was 74.8% ± 2%, including all causes of death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 4,040 patients, 347 patients died as a result of PLGG and 78 patients died of other causes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We performed a multivariate Cox model analysis (Table II) and identified an increased risk of cancer-specific death in children who were treated with radiation therapy (HR = 3.9, P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term survival and late mortality: Ontario population-based cohort
“At a median follow-up of 12.73 years (range, 0.02-33 years), only 93 deaths (7.7%) were recorded, and the 20-year OS rate was 90.1% ± 1.1%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Children with neurofibromatosis type 1 had excellent survival and no tumor-related deaths during adulthood.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with unresectable tumors surviving more than 5 years after the diagnosis, upfront radiotherapy was associated with an approximately 3-fold increased risk of overall late deaths (hazard ratio [HR], 3.3; 95% confidence interval [CI], 1.6-6.6; P = .001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast to early deaths, late mortality was associated not with PLGG progression but rather with tumor transformation and non-oncological causes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Survival by extent of resection and progression rates in a molecularly profiled cohort
“If complete surgical resection is possible, 10-year progression-free survival (PFS) exceeds 85%, but drops below 50% if there is radiologically visible residual tumor” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, only 7.5% of patients succumbed to their disease (median time to death=3.9 years, median OS follow-up=15.9 years) despite 33% experiencing tumor progression (median time to progression=2.3 years, median PFS follow-up=5.9 years) (Figure 1F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcome after first-line chemotherapy: COG A9952 carboplatin and vincristine versus TPCV
“Of 274 randomly assigned patients who met eligibility requirements, 137 received CV and 137 received TPCV. The 5-year event-free survival (EFS) and overall survival (OS) rates for all eligible patients were 45% ± 3.2% and 86% ± 2.2%, respectively. The 5-year EFS rates were 39% ± 4% for CV and 52% ± 5% for TPCV (stratified log-rank test P = .10; cure model analysis P = .007).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Five-year EFS was 19% ± 7% for patients younger than age 1 year, 51% ± 4% for those age 1 to 5 years, and 64% ± 4% for those older than 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcome after first-line chemotherapy: SIOP-LGG 2004 vincristine and carboplatin with or without etoposide
“Response and non-progression rates at 24 weeks for VC and VCE, were 46% versus 41%, and 93% versus 91% respectively; 5-year Progression-Free Survival (PFS) and Overall Survival (OS) were 46% (StDev 3.5) versus 45% (StDev 3.5) and 89% (StDev 2.1) versus 89% (StDev 2.1) respectively. Age and diencephalic syndrome are adverse clinical risk factors for PFS and OS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcome after first-line chemotherapy: HIT-LGG-1996 long-term follow-up
“Following a median observation of 9.3 years, 10-year overall survival (OS) was 0.94 and 10-year event-free survival (EFS) was 0.47. Ten-year progression-free survival was 0.62 following radiotherapy and 0.44 following chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Supporting other reports, satisfactory PFS in the first years steadily declined without plateau (Fig. 4A), in contrast to an OS of 0.88 at 10 years (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following first or further progressions, 61 (28.2%) of 216 patients eventually received radiotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic course with multiple recurrences and subsequent lines of therapy
“In previously untreated patients with sporadic pLGG, most chemotherapies have 5-year progression-free survival (PFS) rates ranging from 45% to 55%. However, approximately 50% of children will require alternative second-line chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since many children will have multiple recurrences throughout childhood with numerous chemotherapy interventions, alternative therapies are needed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Around 40-50% of PLGG patients require subsequent chemotherapy lines.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although pLGG is a low-grade tumor with an excellent 10-year overall survival (OS) rate of 94%, the 10-year progression-free survival (PFS) rate in case of an indication for systemic treatment with standard of care (SoC) chemotherapy is only 44%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, pLGG may be considered a chronic disease in patients whose tumors are unresectable or cannot be completely resected, who will often require several treatment lines throughout life” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, these chemotherapy regimens appear even less effective in infants with pLGG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors for progression in a UK population-based cohort
“The 5-year overall survival and progression-free survival in the whole cohort were 94.6% and 69.4%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Multivariate analysis identified young age, fibrillary astrocytoma, and extent of surgical resection as significant independent risk factors for progression. Hypothalamic/chiasmatic tumors demonstrated the most sustained tendency to progress.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This discrepancy underlines the chronic nature of the clinical course for patients with these tumors, which threaten life infrequently, yet continue to be at a sustained risk for progression when unresectable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prognosis by molecular alteration: rearrangement-driven versus SNV-driven tumors
“Rearrangement-driven tumors were diagnosed at a younger age, enriched for WHO grade I histology, infrequently progressed, and rarely resulted in death as compared to SNV-driven tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This pattern is evident in BRAF, where tumors with KIAA1549-BRAF have superior outcome to BRAF p.V600E (5-year PFS of 69% for KIAA1549-BRAF versus 52% for BRAF p.V600E, p=0.0058, log-rank test).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prognosis by molecular alteration: low-, intermediate-, and high-risk groups
“pLGG harboring gene fusions or germline NF1 mutations comprise the low risk group. These tumors progress less frequently and often eventually stop growing with very few progressions seen after 10 years and almost no deaths at 20 years follow-up (10-year PFS of 67% and OS of 98%, 20-year PFS and OS of 58% and 96%, respectively) (Figure 7B–C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intermediate risk tumors had a 10-year PFS and OS of 35% and 90%, respectively (Figure 7B–C). However, in contrast to the low risk tumors, these tumors continue to progress with a 20-year PFS of 27% and 20-year OS of 81%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“High risk pLGG include those with H3.3 p.K27M, or BRAF p.V600E with CDKN2A deletion. These tumors almost invariably progress (10-year PFS of 0%) and these patients often succumb to their disease (10-year OS of 41%) (Figure 7B,C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prognosis by molecular alteration: BRAF V600E and CDKN2A deletion
“Patients with BRAF V600E PLGG exhibited poor outcomes after chemotherapy and radiation therapies that resulted in a 10-year progression-free survival of 27% (95% CI, 12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E and wild-type PLGG, respectively (P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-two percent of patients with BRAF V600E-mutant received chemotherapy. Five-year PFS after first-line chemotherapy was 30.4% (95% CI, 13.3% to 47.5%; Appendix Fig A1B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PFS in children with BRAF V600E PLGG was 24.0% (95% CI, 1.9% to 46.1%) and 68.7% (95% CI, 52.8% to 70.2%) for the CDKN2A deleted and balanced tumors, respectively, at 5 years and 0% and 45.9% (95% CI, 21.6% to 70.2%), respectively, at 10 years (P = .005; Fig 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of importance, late deaths related to tumor progression were observed in BRAF V600E PLGG even at 25 years of follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Spontaneous stabilization, growth arrest, and regression
“PLGGs have been reported to spontaneously stabilize or regress” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incompletely resected or unresected tumors may progress, remain stable, or even spontaneously involute.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Malignant transformation
“Importantly this highlights that PLGGs are very unlikely to undergo malignant transformation resulting in tumor-related death, which contrasts with the natural history of ALGGs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Malignant transformation is highlighted postradiotherapy, has been observed even without prior treatment, and is not restricted to the older age group or initial astrocytoma grade II. The frequency of <1% in our cohort is lower than incidence rates in smaller series.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: late mortality among 5-year survivors of childhood CNS tumors in the Childhood Cancer Survivor Study
“Among all eligible 5-year survivors (n = 2821), cumulative late mortality at 30 years was 25.8% (95% confidence interval [CI] = 23.4% to 28.3%), due primarily to recurrence and/or progression of primary disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All-cause mortality at 30 years was higher in 5-year survivors of ependymoma (29.5%) and medulloblastoma (29.0%) than in 5-year survivors of astrocytoma and glial tumors (23.9%; P < .001 for both comparisons) (Figure 1, B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: brain and CNS tumor deaths in United States children and adolescents
“Overall, 2,589 deaths were attributed to primary malignant brain and other CNS tumors. This represents an annual average age-specific mortality rate of 0.62 per 100,000 population and an average of 518 deaths per year caused by primary malignant brain and other CNS tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Causes of early and late death and standardized mortality ratio in a population-based cohort
“Despite the excellent overall outcomes, late deaths occurred up to 23 years after the initial diagnosis, and overall SMR was 16.1 (95% CI, 13.0-19.6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 55 of 803 patients died during the study period (Table 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, although 37% of early deaths (<5 years after the diagnosis) were due to tumor progression, none of the late deaths was attributed to PLGG, and most could be attributed to late effects of therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Subgroups with inferior long-term survival in the Ontario cohort
“In contrast, patients with brainstem and thalamic tumors had significantly lower survival than patients with tumors in the rest of the locations (P < .001; Fig. 1D).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, most of these children who died had received upfront radiotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, less than half of patients with pleomorphic xanthoastrocytoma in our study were long-term survivors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Children younger than 3 years with OPG also emerge as a distinct subgroup with poorer outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Multivariable analysis of late mortality and the factors adjusted for
“In a multivariate analysis adjusted for the age of diagnosis, upfront radiation treatment was the most significant factor associated with late overall deaths and tumor-related deaths (P = .012 and P = .014, respectively; Table 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, to assess the association of all factors simultaneously, Cox proportional regression was used to estimate hazard ratios (HRs) after adjustments for the age of diagnosis, tumor location, pathology, and radiation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Leading cause of death and when deaths occurred
Overall survival at 10, 20, and 30 years in the Ontario population-based cohort
Overall survival by tumor location
“Patients with posterior fossa tumors had an excellent 20-year OS rate of 96.8% ± 1.1%, which was similar to the rates for patients with cerebral hemispheric tumors (89.1% ± 2.7%), OPG (90.6% ± 2.2%), and spinal tumors (89.7% ± 2.7%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Overall survival by histological subtype
“Pilocytic astrocytoma was the most common histological subtype, and these patients exhibited excellent 20-year OS of 95.5% ± 1.7% (Fig. 1C); no significant differences were observed for most histological subgroups (astrocytoma ganglioglioma, mixed glioma, and low-grade astrocytoma not otherwise specified).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“whereas pleomorphic xanthoastrocytoma patients (n = 10) had significantly lower survival (10-year OS, 42.9% ± 20.8%; P < .001; Fig. 1C)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Optic pathway glioma: survival by age at diagnosis and by neurofibromatosis type 1 status
“Young children with OPG diagnosed when they were 3 years old or younger had inferior outcomes in comparison with older children (20-year OS, 80.4% ± 6.1% vs 97.9% ± 1%; P = .007; Supporting Fig. 2 [see online supporting information]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Children with NF1 and tumors affecting the optic pathway had excellent survival outcomes (20-year OS, 95.1% ± 2.4%; SMR, 8.9; 95% CI, 2.3-19.7; Supporting Fig. 3A [see online supporting information]), but they were not significantly better than those of OPG patients without NF1 (20-year OS, 88.7% ± 3.6%; SMR, 17.5; 95% CI, 7.9-30.7; P = .06; Supporting Fig. 3B [see online supporting information]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Summary: MAPK pathway activation and oncogene-induced senescence
pLGG is described as predominantly a single-pathway disease in which somatic or germline alterations converge on constitutive activation of the RAS/RAF/MEK/ERK (MAPK) pathway. KIAA1549::BRAF fusions arise from a tandem duplication at 7q34 that removes the N-terminal regulatory domain of BRAF, producing RAS-independent, dimeric RAF signaling. BRAF p.V600E acts as a phosphomimetic that produces constitutive monomeric kinase activity. Germline NF1 loss removes a negative regulator of RAS. Tumors without an identified driver show similar levels of MAPK pathway up-regulation. Sustained MAPK activation also induces oncogene-induced senescence mediated by p16(INK4a) and the senescence-associated secretory phenotype, which was found in 46 of 52 pilocytic astrocytomas (88.5%) and is proposed to explain slow growth and rare progression. CDKN2A deletion, which co-occurs with BRAF p.V600E, is associated with escape from senescence. Type I BRAF inhibitors are limited to BRAF V600E tumors because they can paradoxically activate MAPK signaling in RAF fusion-driven tumors.
BRAF fusion: loss of the BRAF regulatory domain and RAS-independent dimeric signaling
“This rearrangement resulted in the N-terminal regulatory domain of BRAF being lost, leading to downstream up-regulation of the RAS/MAPK signaling pathway” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BRAF fusion-positive tumors demonstrate constitutive, RAS-independent, dimeric RAF signaling, resulting in sustained MAPK pathway activation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, activating BRAF point mutations, most commonly BRAF p.V600E (15–20% of pLGG), result in constitutive monomeric kinase activation and define a biologically and clinically distinct subgroup” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BRAF V600E: constitutive kinase activation
Single-pathway disease: MAPK up-regulation including tumors without an identified driver
“Pediatric low-grade glioma is predominantly a single pathway disease driven by alterations in the mitogen-activated protein kinase (MAPK) signaling pathway (also known as the RAS-RAF-MEK-ERK pathway).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interestingly, all tumors had significantly increased ppERK as compared to normal brain controls (p<0.0001, ANOVA) (Figure 3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“indicating similar levels of RAS/MAPK up-regulation in pLGG lacking a clear molecular driver” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NF1: loss of neurofibromin as a negative regulator of RAS
Oncogene-induced senescence in pilocytic astrocytoma
“Our results indicate that PAs are senescent as evidenced by marked senescence-associated acidic β-galactosidase activity, low KI-67 index, and induction of p16(INK4a) but not p53 in the majority of 52 PA samples (46 of 52; 88.5%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“OIS may account for the slow growth pattern in PA, the lack of progression to higher-grade astrocytomas, and the high overall survival of affected patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“BRAF activation in human neural stem and progenitor cells initially promotes clonogenic growth in soft agarose, suggesting partial cellular transformation, but oncogene-induced senescence subsequently limits proliferation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Immunohistochemical examination of 66 pilocytic astrocytomas revealed p16 INK4a immunoreactivity in the majority of cases, but patients with tumors negative for p16 INK4a had significantly shorter overall survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Senescence-associated secretory phenotype
“MAPK signaling induces oncogene-induced senescence (OIS), which may cause unpredictable growth behavior of pilocytic astrocytomas.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We provide evidence for the SASP regulating OIS in pediatric pilocytic astrocytoma, with IL1B as a relevant mediator.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“High IL1B and SASP expression in pilocytic astrocytoma tumors was associated with favorable progression-free survival.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While pLGG harbors fewer somatic driver alterations relative to other cancers, they also harbor significant transcriptional heterogeneity, with cells expressing MAPK programs, cell-cycle programs, and senescence programs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Paradoxical MAPK activation by type I BRAF inhibitors in RAF fusion-driven tumors
“The use of type I BRAF inhibitors is limited to patients with tumors harboring a BRAF V600E mutation due to the risk of paradoxical activation of the MAPK pathway and accelerated tumor growth if used in patients with tumors harboring a RAF fusion, such as those involving BRAF or CRAF/RAF1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect of prolonged MAPK inhibition on senescence
“The impact of prolonged MAPK pathway inhibition on oncogene-induced senescence (OIS) in pLGG remains unknown and it represents an important gap in understanding what could be the long-term biological consequences of targeted therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Absence of late progression-related death as clinical evidence for oncogene-induced senescence
“Indeed, none of the NF1 patients died in adulthood, and none of the other PLGG adult survivors in this study died of tumor progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These intriguing observations support the current biological hypothesis that in RAS/MAPK-driven tumors, oncogene-induced senescence causes spontaneous growth arrest and tumor burnout in adolescent and young adults with PLGG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Natural history of pilocytic astrocytoma as cycles of growth and dormancy
“The natural history of PA is unique, as these tumors are self-containing, almost never progress to higher-grade astrocytomas, and their initial growth is usually followed by a decrease in tumor activity, after which they enter a dormant phase and either remain quiescent or restart cycle (s) of growth followed by dormancy, similar to what is observed in OIS in vitro.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, artificial acceleration of this OIS program could present an interesting therapeutic possibility in patients with progressive disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Senescence-associated secretory phenotype expression and progression-free survival by resection status
“We here show that a high SASP sum score is associated with favorable progression-free survival (PFS) independent of tumor resection status. We identify two distinct patient cohorts, one with high or intermediate SASP and complete resection (100% 3-year PFS), and one with low SASP and incomplete resection (0% 3-year PFS).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Non-response of senescent tumor cells to chemotherapy and MEK inhibition
“No significant response to carboplatin, vincristine, or trametinib was detected in senescent DKFZ-BT66 cells” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, addition of a BCL2 family inhibitor to the standard-of-care treatment regimen for patients with pilocytic astrocytoma could help eradicate senescent pilocytic astrocytoma cells, which do not respond to chemotherapy and might be the source of tumor recurrence or progression at a later time point.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Reversal of growth arrest by anti-inflammatory treatment
“Treatment with the broad anti-inflammatory drug dexamethasone, however, induced proliferation, exemplary inhibition of the IL1 pathway, and suppression of the SASP in DKFZ-BT66 cells in OIS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As dexamethasone is a drug commonly used in pediatric clinical practice, this result is potentially of high clinical relevance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The SASP can induce growth arrest in proliferating pilocytic astrocytoma cells, while suppression of the SASP by anti-inflammatory treatment leads to bypass of growth arrest.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Determinants of the induction and level of oncogene-induced senescence
“Limiting signals affecting induction and levels of OIS may be dictated not only by the initiating genetic alteration but also by the threshold (intensity and duration) of the signaling and/or the tissue type (cell of origin, microenvironment including the stroma and immune response).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This can explain the dichotomy between activation of an oncogenic pathway, which was recently found to be constitutively activated in 75% to 100% of PAs, and their tendency toward growth arrest.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
MEK inhibition in the senescence model and the limits of a single cell line
“An increase in metabolic activity in both proliferating and senescent DKFZ-BT66 cells was observed under trametinib treatment, as we have described previously” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The current lack of appropriate models beyond DKFZ-BT66 prevents reproduction in a second cell line, and as such represents a limitation of this study, highlighting the urgent need for new additional models at the same time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Follow-up studies are warranted to assess the clinical impact of the use of anti-inflammatory (and immunosuppressive) drugs such as, for example, dexamethasone in pediatric patients with pilocytic astrocytoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Summary: imaging, histology, and molecular testing
Diagnosis combines MRI with histopathology and molecular testing in an integrated, layered report, as endorsed by WHO CNS5. Molecular assays used for pLGG include immunohistochemistry for BRAF p.V600E, fluorescence in situ hybridization, RNA-based multiplex fusion panels (NanoString), next-generation sequencing panels, and DNA methylation profiling. Consensus reviews state that testing must detect structural variants and fusions, copy-number alterations, and single nucleotide variants. In a German population-based cohort of more than 1,200 children, multi-omic integration refined the diagnosis through a DNA methylation class in 50% and detected diagnostic or therapeutically relevant alterations in 47%. In the United States, FoundationOne CDx was approved as a companion diagnostic for OJEMDA in January 2025. Biopsy may be omitted for visual pathway gliomas with characteristic MRI findings, particularly in children with NF1; 115 of 1,031 children (11.2%) in HIT-LGG-1996 and 68 of 497 patients (13.7%) in the SIOP-LGG 2004 randomized trial had no histological verification.
Integrated and layered diagnosis under WHO CNS5
“Such reports feature an integrated diagnosis at the top, followed by layers that display histological, molecular, and other key types of information (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Another key concept in the 2021 WHO CNS tumor classification is the recommendation to utilize integrated and layered diagnoses including tumor site, a combination of a tissue-based histologic diagnosis and molecular diagnosis, histopathological classification, CNS tumor grade, and molecular information.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Molecular testing methods: immunohistochemistry, FISH, RNA fusion panels, sequencing, and methylation profiling
“With respect to pLGG, IHC has been faithfully utilized in the detection of BRAF p.V600E” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“FISH is widely available and can be used on FFPE material but is relatively labor-intensive, and can only test for a single alteration at a time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NanoString panels can be used to screen for the common fusions such as those involving BRAF (including both the canonical KIAA1549-BRAF and the non-canonical fusions described above) and FGFR1-TACC1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sequencing based approaches have the benefit of simultaneous detection of most clinically relevant alterations in a single test from which diagnostic, prognostic and therapy decisions can be made.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the utility of the methylation classifier may be less robust in pLGG, possibly due to frequent inclusion of normal tissue in these tumors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consensus recommendations on the scope of molecular testing
“At a minimum, assays need to be designed to detect genetic alterations that are relevant to pLGG. An integrated approach that is sufficient to detect structural variants/copy-number alterations, single nucleotide variants, and expressed fusion proteins to help inform histopathological interpretation is essential.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, comprehensive molecular profiling using platforms capable of detecting SNVs, copy-number changes, and structural variants (including gene fusions and internal tandem duplications [ITDs]) is integral to contemporary practice” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multi-omic neuropathology in a population-based pediatric cohort
“We show that the multi-omic integration increased diagnostic accuracy in a substantial proportion of patients through annotation to a refining DNA methylation class (50%), detection of diagnostic or therapeutically relevant genetic alterations (47%) or identification of cancer predisposition syndromes (10%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the most commonly affected gene BRAF (272/1,034), fusion events were observed in 158 of 237 DNA methylation-defined infratentorial (124/160), midline (28/51) or cortical LGG (6/26), whereas V600E mutations were further observed in GG (7/13) and PXA (17/23).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States practice: routine genomic profiling and companion diagnostic
Diagnosis without biopsy: visual pathway gliomas and NF1
“Initial surgical intervention achieved complete resection in 34.8% of patients, 204 tumors underwent biopsy only (19.8%), and 115 children received a diagnosis of tumor on the basis of neuroradiologic findings (11.2%), with 65 being NF-1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For VP gliomas, MRI criteria combined with clinical information, such as NF-1 status, allowed diagnosis of the presence of an LGG and justified dispensing with a biopsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“although outside the VPs, LGG histology should be confirmed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Children with chiasmatic-hypothalamic tumours may be eligible without histological diagnosis, if neuroradiologic findings meet unequivocal criteria for the presence of a low grade glioma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sixty-eight patients (13.7%) did not have verification biopsy of the LGG, due to unequivocal neuroradiological appearances.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, chiasmatic-hypothalamic tumors intrinsic to the optic pathway were eligible without pathologic confirmation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Historically, NF1-pLGG are not biopsied due to their precarious location and the lack of clinical utility of the additional information obtained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, obtaining a biopsy from, at minimum, patients deemed higher risk, may prove valuable in identifying patients that require refined and/or novel treatments and distinguishing them from NF1-HGG, particularly in adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Molecular testing of midline tumors that are not routinely biopsied
“Of importance, the mutation was common in midline tumors, including optic pathway, brainstem, and spinal cord tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For deeply located tumors, such as hypothalamic/chiasmatic LGGs, the need for biopsy before treatment decisions are made for these children is still debated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Imaging: MRI standards and response assessment
“RAPNO recommends that baseline brain MRI (or baseline spine MRI depending upon the primary lesion location), be performed pre-operatively and 24–72 h post-operatively, and that the post-operative scan should be utilized as the new baseline for response to systemic (and RT) therapy assessments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RAPNO specifically recommends utilizing T2/FLAIR images to measure a tumor and in assessing radiographic response, as contrast enhancement in pLGG is an unreliable measure of tumor response or progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When a symptomatic NF1-OPG is suspected, MRI of the brain with dedicated high-resolution sequences of the optic nerves and chiasm is the imaging technique of choice to evaluate the extent of OPG involvement and to monitor for radiographic progression or response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
European guideline: observation versus treatment after diagnosis
“Following incomplete resection observation is recommended, as long as there is no radiologic tumor growth and the patient does not suffer from significant, tumor-related symptoms. This also applies to patients with a diagnosis of LGG on the basis of radiological criteria. By contrast, clinical worsening and / or radiologic progression are an indication to treatment with either chemo- or radiotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tiered molecular testing pipeline and turnaround time per tier
“Our tiered testing pipeline included three sequential stages, each increasing in cost and TAT as they progress. Tier 1 consisted of IHC. Tier 2 included FISH or an RNA-based targeted gene fusion panel (NanoString nCounter).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“LGG samples underwent Tier 1 IHC testing to assess BRAF p.V600E and IDH1 p.R132H (the latter if over age 10 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TAT was defined as the time it takes from the acquisition of the tumor sample until a clinical report is generated in business days. The TAT per test is 2 days, 7 days, and 14 days for Tier 1, Tier 2, and Tier 3, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Testing yield in pediatric low-grade glioma and the proportion receiving a targeted agent
“Using our tiered approach, 95% (78 of 82) of LGGs were successfully molecularly characterized.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Within the LGG cohort, 95.1% (78 of 82) of patients had a targetable alteration detected using the tiered approach. Interestingly, only 23% (18 of 78) of those received a targeted agent at some point during therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the remaining 60 patients with a targetable alteration, 30 underwent a curative total resection and were subsequently monitored.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Yield of a tiered molecular characterization pipeline in pediatric glioma
“Overall, the tiered approach successfully identified a molecular alteration in 96% (95 of 99) of gliomas diagnosed over a 2-year period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Within the LGG cohort, 95.1% (78 of 82) of patients had a targetable alteration detected using the tiered approach.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Tumor location as the determinant of presentation: anatomical distribution
“At the population-level, tumors were distributed equally between the diencephalon (n=313, 32%; n=124, 13% were from Neurofibromatosis Type 1 [NF1] patients), cerebral hemispheres (n=265, 27%) and the cerebellum (n=252, 26%), whereas pure brainstem (n=92, 9.4%), spinal cord (n=41, 4.2%) and extensively disseminated tumors (n=13, 1.3%) were less frequent (Figure 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median age of diagnosis was 7.6 years (range 0–18.7 years)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anatomically implicated were 31.6% cerebellum, 24.6% chiasma/hypothalamus, 16.0% cerebral hemispheres, 9.9% brain stem, 6.1% other supratentorial midline structures, 5.9% optic nerve only, 4.5% spinal cord, and 1.4% others.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Raised intracranial pressure and posterior fossa symptoms: headache, vomiting, ataxia, and papilloedema
“nausea and vomiting (75%), headache (67%), abnormal gait and coordination (60%), and papilloedema (34%) for posterior fossa tumours” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Symptoms of raised intracranial pressure were absent in more than half of children with brain tumours.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“macrocephaly (41%), nausea and vomiting (30%), irritability (24%), and lethargy (21%) for children aged under 4 years with intracranial tumours” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual symptoms: optic pathway glioma
“reduced visual acuity (41%), exophthalmia (16%), and optic atrophy (15%) for children with an intracranial tumour and neurofibromatosis” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“headache (49%), abnormal eye movements (21%), squint (21%), and nausea and vomiting (19%) for central brain tumours” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Optic pathway gliomas (OPGs) occur in 15%-20% of children with neurofibromatosis type 1 (NF1); up to half become symptomatic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a study of 57 children with NF1-OPG, only 32 (59%) had signs or symptoms attributable to their tumor at diagnosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because vision deficits due to NF1-OPG may go unnoticed and even precede a diagnosis of OPG, ophthalmologic abnormalities found at tumor presentation and thought to be chronic may not require therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine symptoms: precocious puberty, growth failure, and hypothalamic dysfunction
Nutritional symptoms: diencephalic syndrome in infants with hypothalamic-chiasmatic glioma
“DS typically manifests in the first year of life with profound cachexia, normal or increased appetite, preserved height velocity, and characteristic features including hyperactivity, euphorism, and visual pathway involvement. Low-grade gliomas of the hypothalamic–chiasmatic region, particularly pilocytic astrocytomas, represent the predominant underlying pathology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diagnostic delays averaging 11 months contribute to irreversible complications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By clinical definition, 28 children had DS, with hypothalamic-chiasmatic glioma (26/28) and a high frequency of primary dissemination (6/28). Their median age at diagnosis was 6.5 months (range, 2.4–27.1 mo; 23/28 <1 y).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Brainstem and spinal cord symptoms: cranial nerve palsies, gait disturbance, and back pain
“abnormal gait and coordination (78%), cranial nerve palsies (52%), pyramidal signs (33%), headache (23%), and squint (19%) for brainstem tumours” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“back pain (67%), abnormalities of gait and coordination (42%), spinal deformity (39%), focal weakness (21%), and sphincter disturbance (20%) for spinal-cord tumours” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Symptoms prompting nonsurgical treatment at diagnosis
“Indications for immediate therapy were severe neurologic symptoms (67), visual impairment (74), and risk for tumor progression at a critical site (10)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 115 subjects, visual acuity (VA) decline and tumor progression were the primary reasons to initiate treatment, although there were significant differences in the pattern of indications cited among the institutions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ranked symptoms and signs in children with neurofibromatosis type 1 and an intracranial tumour
“The ranked symptoms and signs were reduced visual acuity (41%), exophthalmia (16%), optic atrophy (15%), squint (13%), headache (9%), unspecified symptoms of raised intracranial pressure (8%), precocious puberty (8%), abnormal gait or coordination difficulties (7%), voice abnormalities (6%), developmental delay (5%), papilloedema (5%), and reduced visual fields (5%; figure 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ranked symptoms and signs at diagnosis in children younger than 4 years
“Ranked symptoms and signs at diagnosis were: macrocephaly (41%), nausea and vomiting (30%), irritability (24%), lethargy (21%), abnormal gait and coordination difficulties (19%), weight loss (14%), clinically apparent hydrocephalus (bulging fontanelle, splayed sutures; 13%), seizures (10%), papilloedema (10%), headache (10%), unspecified focal neurological signs (10%), unspecified symptoms of raised intracranial pressure (9%), focal motor weakness (7%), head tilt (7%), altered level of consciousness (7%), squint (6%), abnormal eye movements (6%), developmental delay (5%), and hemiplegia (5%; figure 2)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Interval between symptom onset and diagnosis
“The reported median symptom interval ranges from 1 to 27 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing awareness of the varied and complex symptomatology that often occurs with CNS tumours could help tumour diagnosis and reduce the extended symptom interval experienced by many children.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Representation of low-grade astrocytoma in the pooled presentation data
“Apart from optic pathway gliomas, these astrocytomas were under-represented in the studies identified.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Despite this result, the distribution of tumour location in the studies identified here was similar to that seen in clinical practice (56% infratentorial, 23% hemispheric, 21% central), lending support to the analysis results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Under-recording of behavioural change and school difficulties at presentation
“In the meta-analysis, the frequency of change in behaviour or school performance (7% in all brain tumours, and 9% for central tumours) was lower than that reported by many individual studies. Several large cohorts reported a frequency of school difficulties and behavioural changes of 22-72%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adults with brain tumours are often not asked about behavioural change, and similar reporting errors probably occur in children.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The assumption was made that if a symptom or sign was not described in a study, it did not occur in that population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Presenting features in a sporadic optic pathway glioma cohort
Long-term morbidity
Summary: tumor- and treatment-related late morbidity
Among 240 five-year survivors in a St. Jude cohort of 361 children, the 15-year cumulative incidence was 18% for monocular blindness, 22% for hearing loss, 29% for growth hormone deficiency, 33% for thyroid hormone deficiency, 26% for ACTH deficiency, 53% for overweight or obesity, and 38% for at least one seizure; 34% of 182 survivors tested had an IQ below 85, compared with 16% in the normative sample. Among children with progressive hypothalamic/chiasmatic tumors, the cumulative incidence of monocular blindness was 57% at 15 years. In a Dutch nationwide cohort of 117 children treated for optic pathway glioma, 18.8% had binocular severe visual impairment or blindness after a median of 8.3 years. In the Childhood Cancer Survivor Study, survivors of astrocytoma and glial tumors showed radiotherapy dose-dependent impairment in attention, processing speed, and memory, and cranial radiotherapy of 50 Gy or more was associated with a 25-year cumulative incidence of CNS subsequent neoplasms of 7.1%, compared with 1.0% without radiotherapy. Chemotherapy is associated with myelosuppression, peripheral neuropathy, allergic reactions, and other toxicities; grade 3 to 4 peripheral nervous system toxicity occurred in 19% of children receiving carboplatin and vincristine in COG A9952.
Cumulative late effects among 5-year survivors: St. Jude cohort
“OS at 15 years was 86% (95% confidence interval [CI] 82%–90%), and PFS was 55% (95% CI 51%–58%). Among the 240 5-year survivors, the 5-, 10-, and 15-year cumulative incidence of adverse outcomes included blindness: 10%, 13%, and 18%, respectively; hearing loss: 8%, 14%, and 22%; obesity/overweight: 18%, 35%, and 53%; hyperinsulinism: 1%, 5%, and 24%; growth hormone deficiency: 13%, 27%, and 29%;thyroid hormone deficiency: 16%, 28%, and 33%; and adrenocorticotropic hormone (ACTH) deficiency: 12%, 22%, and 26%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Survivors of childhood LGG experience substantial long-term adverse effects that continue to increase well beyond the 5-year survival time point.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual impairment
“Lesions in the hypothalamic/chiasmatic region were responsible for most cases of vision loss (27 of 31, 87%), and among patients with progressive gliomas in this location the cumulative incidence of monocular legal blindness was 57% at 15 years from diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, the cumulative incidence of a measured visual field deficit was 31.5% (95% CI 22.7%–40.3%) at 15 years, with a cumulative incidence of over 47% in hypothalamic/chiasmatic lesions, regardless of the progression status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After a median follow‐up of 8.3 years (range: 0.1–23.8 years) after the start of treatment, severe VI or blindness (>1.0 LogMAR) was observed in both eyes in 18.8% of 117 patients and in 34.6% of 234 included eyes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Independent prognostic factors for severe VI or blindness included starting therapy under the age of 2 years and hypothalamic involvement of the OPG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At completion of chemotherapy, VA improved (32% of subjects), remained stable (40%), or declined (28%). Tumor location was the most consistent prognostic factor for poor VA outcome. There was poor correlation between radiographic and VA outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine dysfunction and hypothalamic obesity
“In Cox's multiple regression analysis, both location in the diencephalon and use of RT were statistically significant independent predictors of development of each of these outcomes (Table 4), while GTR was protective for development of GH deficiency (HR = 0.2, 95% CI 0.1–0.6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistent with a known risk for hypothalamic injury-mediated obesity, 75% of these patients are overweight or obese.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hearing loss
“The cumulative incidence of hearing loss was 8%, 14%, and 22% (95% CI at 15 years 13.2–30.3) at 5, 10, and 15 years, respectively, but a deficit severe enough to recommend a hearing aid was uncommon (6%) at 15 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neurocognitive deficits
“Sixty-one patients (34%) had an IQ score <85, compared with 16% in the normative sample (z = 0.18, P < .001, z-test for testing 1 sample proportion).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the multiple regression model, younger age at diagnosis (P = .016), epilepsy (P = .048), and shunt placement (P = .029) were significantly predictive of lower IQ.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Seizures and epilepsy
“The cumulative incidence of at least 1 seizure was 38.0% (95% CI 29.5%–46.5%) (Table 2). Both seizure and epilepsy were associated only with tumor location above the tentorium cerebri, but not with extent of resection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Late effects of radiotherapy: subsequent neoplasms, vasculopathy, and chronic conditions
“Patients who received cranial RT of 50 Gy or more (n = 813) had a cumulative incidence of a subsequent neoplasm within the CNS of 7.1% (95% CI = 4.5% to 9.6%) at 25 years from diagnosis compared with 1.0% (95% CI = 0% to 2.3%) for patients who had no RT. Survivors had higher risk than siblings of developing new endocrine, neurological, or sensory complications 5 or more years after diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was a dose-dependent association between RT to the frontal and/or temporal lobes and lower rates of employment, and marriage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although radiation therapy (RT) is an effective treatment modality for pLGG, it is associated with substantial risk of late effects, including neurocognitive deficits, endocrine abnormalities, secondary malignancy, and vascular complication; therefore, it is not recommended for the majority of children diagnosed with pLGG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Young children are more at risk for late effects of radiotherapy, including decrease in intellectual function, endocrine deficits, second neoplasms, hearing loss, and vasculopathy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“however the hazard ratio of death due to non-glioma related causes of 2.4 (P-value = 0.0006) in patients treated with radiation suggests that radiation-induced mortality may have accounted for some of the deaths that were not directly due to glioma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Toxicity of first-line chemotherapy
“Chemotherapies have many associated toxicities, including risks for myelosuppression, peripheral neuropathy, allergic/anaphylactic reaction, constipation, sodium dysregulation, secondary malignancy, and renal and hepatic dysfunction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic disease burden across functional domains
“Although there is high associated morbidity, tumor-related mortality is relatively rare. pLGG is now conceptualized as a chronic disease, underscoring the importance of functional outcomes and quality-of-life measures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The late adverse effects of the disease and treatment of it in combination with the damage to important functional structures puts a heavy burden on patients and can lead to loss of visual function and impairment of neurologic, endocrine, and cognitive functioning” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The diverse domains that can potentially be affected are described as follows: motor function, speech, eating and swallowing, sensory functions, seizures, neuropathy, organ function after systemic treatment, late effects due to cranial radiation (vascular changes and secondary tumors, endocrine and hypothalamic function, sleep and energy, neuro-cognition and education, psychosocial effects, and quality of life.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity at long-term follow-up after first-line chemotherapy for optic pathway glioma
“With an average follow-up of 6.5 years, VA improved or remained stable in 59% and 61% of children with NF1 and sporadic OPGs, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These findings raise the question as to whether chemotherapy is effective in preserving vision; it may well be that treatment after a certain point of visual deterioration cannot prevent further decline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Residual morbidity and disability grade in survivors and their relation to quality of life
“Despite the improved management and survival of pediatric low-grade glioma, roughly 80% of all survivors experience some morbidity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Greater disability was weakly but significantly correlated with lower scores on the proxy-evaluated total quality of life (r=-0.32, p<0.05). Disability also correlated with lower scores on the friends subscale (r>-0.3, p<0.05) in both the self- and proxy reports.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Academic achievement and delayed emergence of cognitive impairment
“Since the majority of pediatric LGG patients are survivors with the lasting effects of brain injury, they frequently are in long-term need for healthcare resources” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Problems with academic achievement play a role in 60% of LGG survivors, and over years, developmental problems can continue, and even worsen. Cognitive impairments may appear years after diagnosis, even in children without initial severe deficits.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Neuropathy and renal toxicity attributable to first-line vincristine and carboplatin
“The first-line chemotherapeutic treatment for low-grade glioma patients is the combination of vincristine and carboplatin. Peripheral neuropathy due to vincristine occurs during 57% of LGG treatment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Carboplatin can cause kidney damage resulting in hypomagnesemia, rarely indicating supplement and sometimes hypocalcemia and distal renal tubular acidosis” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Frequency of neurologic impairment by domain in children with low-grade glioma
“Children with LGG may experience a diversity of neurologic impairments, including ataxia 40%, motor weakness 44%, seizures 16%, cranial nerve deficits 14%, eye movement disorders and/or visual impairment 46%, and hearing loss 16% and also cognitive dysfunction 36%” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine and hypothalamic dysfunction at 30-year follow-up and what it requires of monitoring
“After a 30-year follow-up, patients encounter GH deficiency in 40%, central precocious puberty in 26%, gonadotropin deficiency in 20%, thyroid dysfunction in 13%, and ACTH deficiency in 13%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally to endocrine dysfunction also hypothalamic damage can be present especially in LGG of the supratentorial midline. These patients have twofold increased risk of endocrine deficiencies” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A proper attention for diverse features of hypothalamic dysfunction is needed: hyperphagia, hypophagia, body mass index, behavioral problems, sleep-wake problems, and temperature instability due to autonomic dysregulation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Seizures after resection and hearing loss after surgery or platinum chemotherapy
“Also after the resection of hemispheric pLGG, seizures can occur, not only directly after surgery (ranging from 15 to 70%), but also on the long term in approximately 30% of patients” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“About 10% of children experiences hearing loss after surgery on an LGG in the cerebellum” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For this reason, carboplatin has been used most often in the treatment of pediatric LGG with lesser risk of hearing loss” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Occupation, income, and education in adulthood after radiotherapy
“On the long term, younger age at diagnosis and treatment with radiotherapy in LGG patients resulted in sevenfold lower occupation scores, more sheltered work, lower income, and less education in adulthood” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This lower occupation score was also related to vision, hearing, and motor impairments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Burden of RAF-altered pediatric low-grade glioma requiring first-line systemic therapy
Humanistic burden and health-related quality of life
Summary: health-related quality of life in pLGG
No study was identified that reports health-related quality of life (HRQoL) specifically in RAF-altered pLGG at the start of first-line systemic therapy, and no published patient-reported outcome (PRO) comparison of first-line chemotherapy versus a MAPK pathway inhibitor was located. Available evidence comes from survivorship cohorts, optic pathway glioma (OPG) cohorts, single-arm chemotherapy trials, and HTA testimony.
In a Mayo Clinic cohort of 121 survivors (median follow-up 21.9 years), mean EORTC QLQ-C30 global QoL was 78, compared with 76.4 in a healthy adult reference population; post-operative radiation, deep tumor location, and recurrence were associated with poorer HRQoL, and participants with recurrence reported more financial problems. In a German survey of 49 survivors, survivors rated their QoL higher than peers, but their parents did not. Among 36 children aged 10 years or younger with OPG, parent-proxy vision-specific QoL was lower with greater vision loss. In a Canadian phase 2 trial of weekly vinblastine in 54 chemotherapy-naive children, QoL was reported as not affected during 70 weeks of intravenous treatment. The ongoing phase 3 LOGGIC/FIREFLY-2 trial is collecting PedsQL-Core, PedsQL-Cancer, and PROMIS measures in both arms. In the NICE appraisal of dabrafenib plus trametinib (TA977), patient experts described regular hospital travel, costs, and time commitments with current treatments, and no child-specific utility values were identified; the committee judged that adult utility decrements likely underestimate the HRQoL loss in children.
Caregiver burden is documented for pediatric brain tumors generally: 85% of 40 caregivers of children newly hospitalized with a brain tumor rated distress 5 or greater on a 0 to 10 scale, and in a five-site matched study of 301 caregivers of brain tumor survivors 1 to 5 years after treatment, mothers reported higher caregiver burden, including financial impact, than mothers of comparison youth.
Long-term survivors: EORTC QLQ-C30 and QLQ-BN20 at a median of 21.9 years
“QOL of 121 patients with a diagnosis of LGG from the Mayo Clinic were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30 for cancer in general) and (EORTC QLQ-BN20 specific for brain tumors).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median follow-up was 21.9 years for the participants. Median age at diagnosis was 11.8 years and at assessment was 33 years. Mean (standard deviation) global QOL score for the study was 78 (18) and 76.4 (22.8) in a reference population of healthy adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with tumor recurrence reported lower role functioning (p=0.016), social functioning (p=0.040), and more financial problems (p=0.029) compared to their counterparts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the multivariable analysis, radiation therapy remained an independent predictor of physical and role functioning as well as symptoms related to brain tumors like visual disorders and motor dysfunction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The following tumor and treatment related factors were most consistently associated with poorer QOL: CNS tumor location, post-operative radiation, and tumor recurrence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term survivors: self-report versus parent report (KINDL)
“We surveyed 49 survivors and their parents (KINDL questionnaire).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Despite tumor and treatment-associated morbidity, survivors (25 boys and 24 girls, median age at diagnosis 7.8 years), but not their parents, rated their total quality of life higher than their peers. Although all survivors had some late morbidity, half of them were able to conduct their daily lives without restriction.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These results reflect survivors' effective coping mechanisms and underscore the difficulties of assessing quality of life in pediatric populations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Optic pathway glioma: vision-specific quality of life by degree of vision loss
“Vision specific QOL was assessed by parent proxy using the Children’s Visual Function Questionnaire (CVFQ), and scores were analyzed according to magnitude of visual acuity (VA) loss and presence of visual field (VF) loss. Thirty-six subjects completed the study (53% female) with median age of 4.6 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lower Competence scores were noted in participants with more profound vision loss (P < .05), reflecting a decreased ability to complete activities of daily living (e.g. feeding, grooming).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Children with two visually impaired eyes were rated as having greater difficulty with social interactions and pleasurable activities (Personality subscale, p=.039) compared to those with only one impaired eye.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life during first-line intravenous chemotherapy: weekly vinblastine
“Vinblastine was administered once per week at a dose of 6 mg/m2 intravenously over a period of 70 weeks. Vision, quality of life, neurofibromatosis type 1 (NF1) status, and BRAF mutation/fusion status were also determined and correlated with outcome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment was well tolerated, and quality of life was not affected during treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
LOGGIC/FIREFLY-2: planned patient-reported outcome comparison of tovorafenib versus chemotherapy
“Patient-reported outcomes (PRO) assessments: comparison of changes in quality of life (QoL) and health utilities measures between study arms using the Pediatrics Quality of Life™-Core Module (PedsQL-Core), Pediatrics Quality of Life™-Cancer (PedsQL-Cancer), and Patient-Reported Outcomes Measurement Information System (PROMIS ® ) assessment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PedsQL-Core, PedsQL-Cancer and PROMIS ® are being assessed at Screening, every 52 weeks from week 5 to end of treatment, and at year 5 as part of the LTFU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient and caregiver experience of current treatment and utility values: NICE appraisal of dabrafenib plus trametinib
Caregiver distress at diagnosis of a pediatric brain tumor
“Forty primary caregivers were enrolled (of 49 eligible), with the patient age ranging from newborn to 17 years (mean 7.7 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean and median DT scores were 7.2 (SD 2.6) and 7, respectively. However, 12 (30%) rated their distress 10/10, and 85% rated distress 5 or greater.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Families of children with newly diagnosed brain tumors experience high levels of distress and psychosocial risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver burden in survivorship: caregivers of pediatric brain tumor survivors versus matched comparison caregivers
“As part of a five-site study, we utilized a matched-sample design to evaluate psychosocial functioning of 301 caregivers of 189 PBTS (ages 8-15) who were 1-5 years post-treatment, and 286 caregivers of 187 comparison youth matched for sex, race, and age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers of PBTS reported similar levels of psychological symptoms to caregivers of comparison youth. Mothers of PBTS mothers reported higher caregiver burden and lower perceptions of social support than mothers of comparison youth. Low SES exacerbated group differences in caregiver burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results demonstrated a significant main effect of group status on all subscales, such that mothers of PBTS reported higher levels of financial impact, disruption of planning, caretaker burden, familial burden, and significantly lower levels of coping than mothers of comparison youth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HRQoL in RAF-altered pLGG before the start of first-line therapy
No evidence found.
Parent-proxy global health and fatigue during first-line dabrafenib plus trametinib versus chemotherapy
“The difference in the overall least-squares means of scores between the trial groups for global health and fatigue favored dabrafenib plus trametinib over chemotherapy at all scheduled time points” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Outcomes on the pain subscale were similar in the two groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The clinical benefit of dabrafenib plus trametinib as compared with chemotherapy is further supported by greater improvements in visual acuity and global health.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Domains in which survivor self-report differed from the reference population
“Thirty-three patients age 11-17 years old were included in the self-evaluated quality of life analysis compared with published norms for this age group (Fig. 1)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“They rated their total quality of life, physical well-being, and self-esteem significantly higher than their healthy peers (p<0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychological and social late effects and the state of quality of life evidence
“Pediatric LGG patients have shown increased risk as late effects for social difficulties and psychological problems (e.g., anxiety 19%, depression 15%, fatigue, behavioral problems 13%), even without additional treatment with chemo- and radiotherapy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Quality of life is gaining attention in LGG, but its evaluation still shows inconsistent results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fatigue and adaptive behavior after treatment
“For children, fatigue after a brain tumor still increases up to 8 years after diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adaptive behavior after LGG, measured via the Vineland adaptive behavior scale, is decreased for communication (written skills) and the subdomain gross motor skills. These issues are worse in children with younger age at diagnosis and/or chemotherapy. Residual disease was associated with poorer total adaptive behavior” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Divergent quality of life findings across instruments and the limits of the evidence base
“Sixty-one percent of the patients had impairments (e.g., epilepsy, hormone deficiencies, and motor, visual, sensory, and auditory deficits). Unlike the findings in our study, the Aarsen group reported reduced quality of life for all domains of the TACQOL questionnaire, except in the emotions domain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All four LGG quality of life studies to date have limitations inherent to cross-sectional, single-institution studies. Small sample sizes, of which ours is the largest, decrease the generalizability of the results, reduce the power of the statistical analysis, and increase the chance that differences and correlations within the data may fail to reach a level of significance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Summary: healthcare resource use and costs
No study reporting total direct medical costs of pLGG care in the United States was identified. A Day One-sponsored U.S. study of linked claims and electronic health records (Optum Market Clarity) followed 154 patients aged 18 years or younger with pLGG for 36 months: most patients (95% to 98%) had office or outpatient visits in each 6-month interval, 18% to 28% visited an emergency room, and 9% to 27% had an inpatient stay; mean inpatient stay duration increased from 5.1 days at baseline to 8.1 days during follow-up. Over the study period, 74% of patients filled prescriptions for anti-infectives, 56% for antiemetics, and 65% received pLGG-directed treatment (most often brain surgery); chemotherapy was recorded in 14%. Tumor histology and molecular status could not be characterized.
For long-term survivorship, a Taiwanese national claims study of 33,105 five-year survivors of childhood cancer or benign brain tumor (median follow-up 7 years) reported median annual medical expenses of US $614.08 for brain cancer survivors (n = 2,241) and US $336.89 for benign brain tumor survivors (n = 7,825), versus US $203.90 for 64,754 matched individuals without cancer. No publication was identified that quantifies infusion visit, central venous access, or hospitalization costs of first-line carboplatin and vincristine or vinblastine in pLGG.
U.S. linked claims and EHR study: cohort and overall healthcare resource utilization
“Optum ® Market Clarity Data were used to identify patients aged ≤18 years with an ICD-10 code for brain neoplasm, ≥1 physician notes, and with evidence of pLGG recorded between January 1, 2017 and June 30, 2018. Outcomes including health characteristics, HRU, medications, and procedures were assessed at 6-month intervals over 36 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HRU, including speciality care visits, filled prescriptions, and administered medications, was common; 74% of patients had prescriptions for anti-infectives, 56% antiemetics, and 52% required pain or fever relief. Sixty-five percent of patients underwent treatment to control their pLGG, the most common being brain surgery. Little decline was observed in medication use during the study period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eighty-six patients (56%) received commercial benefits and 68 patients (44%) received Medicaid benefits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with pLGG have complex healthcare needs requiring high HRU, often over a long time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. linked claims and EHR study: sites of care, inpatient stays, and emergency room use
“Most patients (95–98% across the study period) visited an office or outpatient facility, 38–50% a diagnostic laboratory, 18–28% an ER, and 9–27% an inpatient facility in each of the 6-month intervals ( Figure 2D ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the mean inpatient stay duration increased by 59% from 5.1 days during the baseline period to 8.1 days during the follow-up period ( Figure 2E ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Time spent in ER visits and inpatient stays places a substantial burden on families and adds to time spent away from work, school, and normal activities, potentially adding to financial burden and overall stress.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. linked claims and EHR study: pLGG-directed treatments and limitations
“In the overall study period, 65% of patients received pLGG-specific treatment, the most common being emergency brain surgery (55%) and planned brain surgery (27%) ( Figure 3D ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Chemotherapy was given to 14% of patients during the study, with the highest proportion of patients receiving it in the first 6-month observation interval (7%) and its use declining over the follow-up period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In particular, it was not possible to: characterize the tumors histologically or genomically, ascertain the patient’s history of disease, anatomical primary site, or determine their stage on the treatment journey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term survivorship: annual medical expenses of brain tumor survivors (Taiwan national claims)
“A total of 33,105 children had survived for at least 5 years after the first appearance of a diagnostic code of cancer or a benign brain tumor before the age of 18 years from 2000 to 2010 with follow-up to 2015.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Survivors with female gender, diagnosis before the age of 3 years, and diagnosis of brain cancer or a benign brain tumor had significantly higher annual outpatient expenses (all P<.001). Moreover, the analysis of outpatient medication costs showed that hormonal and neurological medications comprised the 2 largest costs in brain cancer and benign brain tumor survivors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Group | Median annual total expense, US $ per person (IQR) |
|---|---|
| Brain cancer survivors (n=2241) | “614.08 (267.05-1793.94)”View highlighted excerpt for this quote |
| Benign brain tumor survivors (n=7825) | “336.89 (184.64-652.14)”View highlighted excerpt for this quote |
| Hematologic cancer survivors (n=3934) | “268.48 (159.50-475.08)”View highlighted excerpt for this quote |
| No cancer individuals (n=64,754) | “203.90 (118.98-347.55)”View highlighted excerpt for this quote |
Direct medical costs of first-line chemotherapy administration, central venous access, and survivorship care in U.S. pLGG
No evidence found.
Economic impact of RAF-altered pediatric low-grade glioma requiring first-line systemic therapy on families
Summary: family financial burden and parental work loss
No study was identified that measures family financial burden specifically in pLGG. Evidence from pediatric brain tumors and pediatric cancer overall indicates the following. At a U.S. cancer center, 16% of 202 patients younger than 21 years who underwent neurosurgery for a cancer-related diagnosis had financial toxicity before surgery, and the 2-year cumulative incidence after surgery was 19%; among 86 patients who survived at least 2 years, 34% experienced financial toxicity, and most affected patients had commercial insurance. In a U.S. single-site survey of 254 caregivers of children with cancer, approximately one third reported that a parent quit or changed work because of the child's cancer, and this was associated with a 13.4-point higher financial burden score (0 to 100 scale) at 1 to 5 years after diagnosis. A systematic review of 35 studies reported frequent parental job loss or job quitting, particularly among mothers, with effects persisting into early survivorship. In a Canadian cohort of 28 families, median first-year indirect costs were $9,668 and median income loss was 55 days. In the Childhood Cancer Survivor Study (3,023 adult survivors; 16% with CNS tumors), survivors with 4 impaired neurocognitive domains had odds ratios of 3.12 for debt collection and 3.77 for bankruptcy compared with survivors with no impaired domains.
Financial toxicity in pediatric and adolescent neurosurgical oncology (United States)
“A retrospective review of medical and financial services data was conducted at Memorial Sloan Kettering Cancer Center of patients under 21 years of age who underwent neurosurgery for a cancer-related diagnosis from 2016 to 2020.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“294 surgical procedures across 202 patients were analyzed. 16% (33/202) of patients experienced FT in the two years prior to the first neurosurgical procedure, and the most common toxicity identifier was utilization of the financial assistance program (45%). For all 202 patients, the 2-year cumulative incidence of FT following first neurosurgical procedure was 19% (CI:14%,24%). Among patients who survived for at least 2 years after surgery, 34% (29/86) experienced FT with the most common toxicity being having bills sent to collections (34%). Most patients who experienced FT had at least one commercial insurance policy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Parental employment disruption and perceived financial burden in pediatric cancer (United States)
“Eligible patients were treated at a pediatric cancer hospital, diagnosed at age ≤ 21 years and were ≤ 5 years from diagnosis (N = 254). Financial burden was rated on a visual analog scale of 0 to 100.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately one third of caregivers in both groups reported a parent quitting or changing work as a result of their child's cancer diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When adjusted for sex, age at diagnosis, insurance status, and rural residence, caregivers whose child was 1 to 5 years from diagnosis with ≥ 5 unexpected hospitalizations experienced 24.9 (95% CI, 9.1 to 40.7; P < .01) points higher financial burden than those with no unexpected hospitalizations. In addition, when compared with families without employment disruptions, families of children 1 to 5 years from diagnosis in which a caregiver had quit or changed jobs reported 13.4 (95% CI, 3.2 to 23.6; P = .01) points higher financial burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review: impact of childhood cancer on parents' socio-economic situation
“Our systematic review included 35 eligible articles. Childhood cancer had a substantial impact on parents' socio-economic situation across all studies. This impact varied largely by geographical region. We observed a high prevalence of disruptions in parental employment such as job quitting or job loss, particularly among mothers. The associated income losses further contributed to families' perceived financial burden in addition to increased cancer-related expenses. Adverse socio-economic consequences were most pronounced shortly after diagnosis, however, persisted into early survivorship for certain groups of parents.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Parents' employment after completion of childhood cancer treatment
“We interviewed 56 parents of childhood cancer survivors (M = 2.13 years after treatment completion; 89% mothers) using the vocational and financial impact section of the Psychosocial Adjustment to Illness Scale-Carer Interview Form.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Parents reported multiple sources of financial toxicity including travel to and from the hospital and needing to reduce their working hours during their child's cancer treatment. Workplace flexibility was an important factor to protect against unwanted vocational changes. After treatment completion, families living in low socioeconomic areas commonly reported ongoing financial difficulties.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Indirect costs and income loss in the first year of childhood cancer treatment (Canada)
“Thirty families participated in the study, with 28 providing financial information and 29 participating in interviews. Financial information was collected during the first year of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Families spent a median of $9668 (IQR $7944-12958) on indirect costs and had a median of 55 (IQR 0-125) days of income lost. Most families (79%) in our study experienced a psychosocial burden using terms like stress, worry, or frustration directly as a result of the financial burdens from cancer treatment, in addition to the already significant anxiety around having a child with cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neurocognitive late effects and financial hardship in adult survivors of childhood cancer (Childhood Cancer Survivor Study)
“The analytic cohort comprised 3023 adult (median age at financial hardship survey 40.5 [IQR 35.0-47.8] years) survivors of childhood cancer with the most common diagnoses being leukemia (31%), central nervous system tumor (16%), and Hodgkin lymphoma (13%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with 4 impaired neurocognitive domains had over 3-fold increased odds of debt collection (OR=3.12, 95% CI=1.91-5.09) and bankruptcy (OR=3.77, 95% CI=2.01-7.07) compared to individuals with no impaired neurocognitive domains.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket costs and parental work loss specific to pLGG or to oral MAPK inhibitor versus intravenous chemotherapy
No evidence found.
Definition of financial toxicity and insurance coverage in the neurosurgical oncology cohort
“Financial toxicity was defined as meeting one or more of the following criteria: bankruptcy, bills sent to collections, settlement on medical bills, participation in a timed payment plan, copay assistance program use, financial assistance program use, social work philanthropy use and expression of financial concerns to social work.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median ZIP-code income, which is the median income living within a zip code, for these patients’ families was $88,636 (range $ 65,101, $116,191). 94% of patients had some type of insurance coverage with 60% of these insured patients being covered by private insurance and 33% by public insurance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Types of financial toxicity and predictors of post-operative financial toxicity
“The most common toxicities were utilization of a financial assistance program (45%), use of social work philanthropy fund (30%), and having bills sent to collections (24%)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common toxicities for patients surviving at least 2 years after last neurosurgical procedure were having bills sent to collections (34%), utilization of the financial assistance programs (31%), and use of the social work philanthropy fund (28%) (Table 2). Among these patients experiencing FT, 69% had at least one commercial insurance policy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In a univariate regression model, only living within the Tri-state area was significantly predictive of developing post-operative FT (p = 0.037) compared to living outside the Tri-state area (Table 3). Age at first procedure, sex, living in New York versus outside of NY, race, type of insurance, and diagnosis (neuroblastoma vs. diffuse midline glioma (DMG) vs. other) were not significantly associated with developing post-operative FT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Proportion of parents who reduced or left employment during their child’s treatment
“Thirty-eight parents (67.9%) reported experiencing disruption to their employment while their child was on treatment, which is encapsulated in two subcategories.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-nine parents (51.8%) reported that they and/or their partner reduced their hours or resigned from their employment after their child’s diagnosis. Participants and their partners reduced working hours by taking unpaid leave (n = 13, 23.2%), taking extended paid leave, including sick and long-service leave (n = 5, 8.9%), changing from full-time to part-time or casual employment (n = 6, 10.7%), changing their self-employed working hours (n = 3, 5.4%), resigning from their employment (n = 12, 21.4%), or a combination of these.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medical appointments as the leading cause of ongoing employment disruption after treatment
“Two-thirds of parents (n = 38, 67.9%) reported that their child’s ongoing cancer-related needs caused disruptions to their employment, barriers to reentering the workforce, or barriers to increasing their working hours to full-time employment. The most frequent disruptions were medical appointments (n = 30, 53.6%) and their child’s ongoing health needs (n = 21, 37.5%; e.g., child being too unwell to attend day-care or school).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Persistence of family financial toxicity after treatment completion
“Only five parents (8.9%; of whom four had an SES decile greater than six and one was unknown) reported that at the time of the study, their financial toxicity related to their child’s cancer treatment had resolved.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Family costs as a proportion of family income in a critical review of cost of illness studies
“The major components of family’s direct costs were travel, food, and child care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Families’ costs, in relation to family income, ranged from 0.2% to 283.1% in the US” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the first hospitalization of insured Mexican children diagnosed with leukemia, parents’ out-of-pocket costs and lost wages were US$ 679 (range US$ 127–1,882) exceeding the total household income for nearly half the families” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Methodological limits of the family cost of illness evidence base
“Existing research indicates that families incur significant variable costs throughout cancer treatment. However, problems with the published studies related to various PQAQ domains (e.g., time horizon, sensitivity analysis) rendered the magnitude of families’ childhood cancer costs somewhat uncertain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All data in the reviewed studies were collected within a 1-year time frame.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“None of the researchers examined how sensitive their results were in relation to the estimates used for particular variables or underlying assumptions” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Scope of the systematic review and timing of employment and income disruption
“Thirteen (37%) studies were conducted in Europe, 16 (46%) in North America/Australia, and 6 (17%) in Asia/Africa (Table 1). Eight (23%) studies included comparison parents. The majority of studies (85%) included different cancer types.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-six (74%) studies reported on employment, 20 (57%) on income, 21 (60%) on financial situation, and 20 (57%) addressed financial assistance (Table 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most work disruptions occurred shortly after diagnosis and attenuated within one year” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Financial toxicity before surgery as a predictor of financial toxicity afterwards
“Patients experiencing preoperative FT within 2 years of their first neurosurgical procedure had a statistically significantly higher cumulative incidence of post-operative FT (2-year estimate: 61% (95% CI: [41%,75%]) compared to their counterparts who did not experience pre-operative FT (2-year estimate: 11% (95% CI: [7%,16%]) (p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This establishes the critical need for assessment and intervention for those at risk of FT prior to meeting criteria and longitudinally throughout treatment, to help decrease the initial and cumulative incidence of FT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver work loss and cost-related medication nonadherence in adolescents and young adults
“In addition, working caregivers often need to take significant time away from work, utilizing unpaid leave, sick leave, a leave of absence, or quitting their job. This caregiver inability to work leads to reduced income and halted career progression” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As the patients age into adolescence and young adulthood, they become more likely to report cost-related nonadherence to medication, inability to afford medication, ask physicians for a lower cost medication, and use alternative therapies compared to a non-cancer control group of similar ages” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Why the measured financial toxicity rate is likely an underestimate
“A notable limitation to this manuscript is that the data are derived from a quaternary cancer care center without a public emergency department. The rates of FT reported are likely lower than in the community due to the inherent barriers involved with navigating the health care system to receive care at a quaternary cancer care center.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Indirect costs are often not captured by hospital financial service departments, and prospectively partnering with patient families is crucial to understanding the impact of indirect costs associated with pediatric neurosurgical oncology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket cost categories and the supports families relied on
“Thirteen parents (23.2%) discussed the factors that directly contributed to their financial toxicity after their child’s diagnosis. Major contributors during their child’s treatment included parking fees, petrol (fuel), and other expenses related to regularly traveling to and from the treating hospital (e.g., road tolls).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-one parents (37.5%) discussed factors that helped protect their family from financial toxicity after their child’s diagnosis and throughout treatment. These included loans, donations, or gifts from friends and family, charitable support (e.g., free accommodation near their child’s treating hospital and petrol/fuel vouchers), government payments (i.e., welfare payments), and receiving paid leave from their employment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Employment effects persisting years after treatment completion
“Nine mothers (16.1%) reported that their child’s ongoing cancer-related needs continued to affect their employment, an average 3.4 years after treatment completion (SD = 3.78). Mothers reported that they accepted lower-paid roles compared with roles prior to their child’s diagnosis, chose part-time or casual employment when they had previously been employed full-time, or chose to leave their employment altogether to become stay-at-home mothers despite expressing their desire to work.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Thresholds for judging family cost burden
“Lansky and coworkers indicated that the direct costs plus loss of pay were, on average, considerably more than 15%. For half of their sample, the figure was over 25%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“According to the studies reviewed, families of children with cancer are experiencing an unfair burden regardless of whether the threshold is 5% or 15%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Factors that drive family costs and resource use
“Presently, socioeconomic status, distance from hospital, cancer type, and length of hospitalization have been reported to significantly influence families’ costs and resource use.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the high likelihood of cure, the costs families incur over the course of treatment may be unsustainable and lead to considerable stress and financial hardship” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiving time required and families at particular risk
“A Swiss study estimated that parents need on average 240 working days for caretaking during the child´s treatment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Also in the US, a study showed that 15% of families fell below the poverty level due to cancer-related financial strains” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We identified families with lower socioeconomic position, parents of children diagnosed with haematological cancers and diagnosed at younger age to be at particular risk for adverse socio-economic consequences.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Summary: cost of molecular testing for BRAF alterations
Tovorafenib use in relapsed or refractory pLGG requires a BRAF fusion or rearrangement or BRAF V600 mutation, and FoundationOne CDx (a tissue-based next-generation sequencing test of 324 genes) was approved by the FDA as its companion diagnostic in January 2025. The Medicare advanced diagnostic laboratory test payment for FoundationOne CDx (code 0037U) was $3,500.00 during its initial period (July 1, 2018 to March 31, 2019); a current 2026 payment rate was not retrieved. No U.S. cost-effectiveness analysis of molecular testing for tovorafenib eligibility was identified.
Reported per-sample costs in other settings were US$1,000 for an outsourced RNA pan-cancer NGS panel (Jordan, 32 pediatric CNS tumors) and, for 82 pediatric LGGs, an average of $405 with a tiered approach (immunohistochemistry, targeted fusion panel or FISH, then targeted RNA sequencing) versus $745 with upfront targeted RNA sequencing. A Canadian microsimulation cost-utility analysis of BRAF fusion testing at diagnosis (100,000 simulated patients; 2018 Canadian dollars; targeted therapies not modeled) found testing dominant, with a gain of 0.38 quality-adjusted life-years (QALYs) and a $1,384 reduction in lifetime costs, driven by avoided radiation-related adverse events.
Companion diagnostic: FoundationOne CDx for tovorafenib
Medicare payment for FoundationOne CDx under the Clinical Laboratory Fee Schedule
| Field | Quoted record |
|---|---|
| Test code | “0037U” |
| Test name | “FoundationOne CDx” |
| New ADLT initial period | “7/1/18 - 3/31/19” |
| Payment amount during new ADLT initial period | “$3,500.00” |
Cost-utility of BRAF fusion testing at diagnosis in pLGG (Canadian microsimulation)
“We performed a model-based cost-utility analysis comparing two strategies: molecular testing to determine BRAF fusion status at diagnosis against no molecular testing. We developed a microsimulation to model the lifetime health and cost outcomes (in quality-adjusted life years (QALYs) and 2018 CAD, respectively) for a simulated cohort of 100,000 patients newly diagnosed with PLGG after their initial surgery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our findings indicate that patients who received molecular testing at diagnosis experienced a 0.38 (95% CI: 0.08;0.77) gain in QALYs and $1384 (95% CI: $-3486; $1204) reduction in costs over their lifetime. Cost and QALY benefits were driven primarily by the avoidance of long-term adverse events (stroke, secondary neoplasms) associated with unnecessary use of radiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Molecular testing was defined as screening glioma tumor samples for BRAF fusion alterations using the NanoString assay (NanoString Technologies, Seattle, WA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We did not include targeted therapies as a possible treatment for PLGG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Per-sample cost of tiered molecular characterization versus upfront targeted RNA sequencing in pediatric glioma
“We used a tiered testing pipeline of immunohistochemistry (IHC), customized fusion panels or fluorescence in situ hybridization (FISH), and targeted RNA sequencing in pediatric gliomas.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average cost per sample was more affordable when using the tiered approach as compared with up-front targeted RNA sequencing in LGG ($405 US dollars [USD] v $745 USD) and HGGs ($282 USD v $745 USD). The average TAT per sample was also shorter using the tiered approach (10 days for LGG, 5 days for HGG v 14 days for targeted RNA sequencing).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost and turnaround of outsourced RNA NGS panel for pediatric CNS tumors (middle-income country)
“We reviewed our experience with NGS testing (TruSight RNA Pan-Cancer-seq panel) for pediatric CNS tumors at KHCC/Jordan (March/2022–April/2023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median turnaround time from samples’ shipment to receiving the results was 23.5 days (range, 15–49 days) with a median laboratory processing time of 16 days (range, 8–39 days) at a cost of US$1,000/sample.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. commercial cost or cost-effectiveness of BRAF testing to select tovorafenib in first-line pLGG
No evidence found.
Molecular testing treated as a routine cost already incurred in a pLGG cost-effectiveness model
“No testing costs are included in this economic evaluation because patients diagnosed with glioma are routinely tested for common driver mutations, including BRAF V600 mutations, via next-generation sequencing panel testing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Unit cost of each tier in the tiered molecular testing pipeline
“To demonstrate the cost benefit of our tiered approach, the mean running cost (including labor cost and consumables) of testing per sample was calculated for the 86 LGG and 18 HGG samples in US dollars (USD), including failed and unsolved samples. The cost of Tier 1 testing is based on a minimum of 3 IHC stains per sample equaling $75 USD. The cost of running the Tier 2 tests is $100 USD per sample, and the cost of running Tier 3 (targeted RNA sequencing) is $745 USD per sample.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Infrastructure required before a tiered testing approach lowers per-sample cost
“It should be noted, however, that a basic infrastructure is required for such an approach including the availability of a laboratory equipped with at least Tier 1 testing and a trained molecular pathologist. The initiation of such infrastructure requires additional up-front nonrecurring costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Distribution of samples across testing tiers, which is what produces the cost difference
“Tier 1, Tier 2, and Tier 3 testing was performed on 98%, 41%, and 35% of samples, respectively. Collectively, 64% underwent either Tier 1 testing alone or Tier 1 and 2 testing, with 64% (52 of 82) not requiring Tier 3 testing (Fig 2A).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Using our tiered approach, 95% (78 of 82) of LGGs were successfully molecularly characterized.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Surgical resection and observation
Surgery as initial treatment and observation after incomplete resection
“Around 40% of all LGG patients can be cured by complete neurosurgical resection and are followed by close observation. In case of relapse, second resection often is possible. Following incomplete resection observation is recommended, as long as there is no radiologic tumor growth and the patient does not suffer from significant, tumor-related symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“By contrast, clinical worsening and / or radiologic progression are an indication to treatment with either chemo- or radiotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Surgical resection is the mainstay of front-line therapy for symptomatic pLGG; however, more than 50% of pLGGs occur in locations that are either not amenable to surgery or only amenable to a biopsy or limited resection (e.g. tumors located in the diencephalon, brainstem, optic pathway, or spinal cord) (8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Indications to start non-surgical treatment in unresectable pLGG
| Category | Indication |
|---|---|
| Radiologic criteria | “Increase of tumour volume of > 25 %” |
| Neurologic symptoms | “Diencephalic syndrome” |
| Neurologic symptoms | “Focal neurologic deficits subsequent to tumour growth” |
| Infants | “Infants below 12 months of age with chiasmatic-hypothalamic tumours” |
| Ophthalmologic symptoms | “Visual deterioration on follow-up, a significant loss is defined as more than or equal to 0.2 LogMAR” |
Brazilian consensus: surgery and molecular testing
“Maximal safe surgical resection remains the cornerstone of treatment for low-grade gliomas (LGG).10 However, precision medicine strategies can inform prognosis and therapeutic decision-making, especially in cases of progressive or recurrent disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LGG1 | For low-grade gliomas, regardless of histological subtype, BRAF gene fusions and BRAF V600E mutation testing should be performed as part of the molecular evaluation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vision loss as the indication for starting chemotherapy in the SIOP-LGG 2004 UK optic pathway glioma cohort
“VA loss was the most frequent indication to initiate therapy in both NF1 (n=34 eyes, 74%) and sporadic (n=39 eyes, 89%) groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Early treatment was initiated in both NF1 and sporadic groups; median time from diagnosis to initiation of treatment was 35 and 21 days, respectively, with 77% and 93% of subjects, respectively, receiving treatment within 1 year of diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Published 2024 recommendations add criteria to start non-surgical treatment beyond the 2022 draft
Conventional chemotherapy
European standard clinical practice: carboplatin and vincristine first line, vinblastine alternative
COG A9952: carboplatin and vincristine versus TPCV in children younger than 10 years
“Of 274 randomly assigned patients who met eligibility requirements, 137 received CV and 137 received TPCV. The 5-year event-free survival (EFS) and overall survival (OS) rates for all eligible patients were 45% ± 3.2% and 86% ± 2.2%, respectively. The 5-year EFS rates were 39% ± 4% for CV and 52% ± 5% for TPCV (stratified log-rank test P = .10; cure model analysis P = .007).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The difference in EFS between the regimens did not reach significance on the basis of the stratified log-rank test. The 5-year EFS was higher for TPCV on the basis of the cure model analysis. Differences in toxicity may influence physician choice of regimens.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SIOP-LGG 2004: vincristine and carboplatin with or without etoposide
“Some 497 newly diagnosed patients (M/F 231/266; median age 4.26 years (interquartile range (IQR) 2.02-7.06)) were randomised to receive vincristine carboplatin (VC) (n = 249) or VC plus etoposide (VCE) during induction (n = 248), stratified by age and tumour site.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Response and non-progression rates at 24 weeks for VC and VCE, were 46% versus 41%, and 93% versus 91% respectively; 5-year Progression-Free Survival (PFS) and Overall Survival (OS) were 46% (StDev 3.5) versus 45% (StDev 3.5) and 89% (StDev 2.1) versus 89% (StDev 2.1) respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The addition of etoposide to VC did not improve PFS or OS. High non-progression rates at 24 weeks justify retaining VC as standard first-line therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly vinblastine in chemotherapy-naive progressive pLGG
“Fifty-four patients were enrolled onto the study, with a median age of 8 years (range, 0.7 to 17.2 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Best response to chemotherapy was centrally reviewed with a response rate (complete, partial, or minor response) of 25.9%. Disease stabilization (complete, partial, or minor response or stable disease) was achieved in 47 patients (87.0%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Five-year overall survival and progression-free survival (PFS) rates were 94.4% (95% CI, 88.5% to 100%) and 53.2% (95% CI, 41.3% to 68.5%), respectively, for the entire cohort.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Chemotherapy outcomes and toxicities summarized by independent reviewers
“While the 5-year overall survival (OS) with chemotherapy ranges from 86-94% on recent studies, 5-year progression-free survival (PFS) is less favorable at 42-45% in pLGG, with slightly better PFS reported in patients with NF1 (5-yr PFS 69-85%) (9, 10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Chemotherapy regimens including carboplatin and vincristine or single-agent vinblastine are commonplace today, and while the adverse effect profile of these agents is relatively well tolerated, they carry risks of myelosuppression, gastrointestinal toxicity, and peripheral sensory and motor neuropathy (9–11).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Standard systemic treatment for pediatric low-grade gliomas (PLGGs) has traditionally been chemotherapy with either carboplatin/vincristine or weekly vinblastine [3,4]. Unfortunately, many patients will progress despite this treatment approach (50%) and a second line of therapy will be needed [3,4].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chemotherapy regimens used as the comparator in LOGGIC/FIREFLY-2
“The SIOPe-BTG LGG WG reported a response rate of 29% (24 weeks after treatment start) and a five-year PFS rate of 45% [9], whereas the COG reported a response rate of 35% (end of treatment) and a five-year event-free survival rate of 39% [8]. A single-arm phase 2 study of single-agent vinblastine (VBL) resulted in a 19% response rate and a five-year PFS rate of 53% [10].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Arm 2 VBL regimen comprises VBL (BSA ≥ 0.6 m2: 6 mg/m2/day, without exceeding 10 mg; BSA < 0.6 m2: BSA dose × 1/30 × body weight [kg]/day) administered IV QW in four-week cycles until completion of treatment at 70 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Schedule and duration of carboplatin and vincristine in the North American and European protocols
“Consolidation lasted from week 13 to 53 and consisted of 4-week cycles of CV with a total duration of chemotherapy of 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who required systemic therapy were treated with CV for 18 months (10 cycles of consolidation compared to HIT-LGG 1996) and non-NF-1 patients were randomized to receive etoposide as an addition to CV during induction phase of therapy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Later on, CV became the most used regimen for newly diagnosed or progressive PLGG around the globe with the reported 5-PFS ranging from 39 to 47%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Carboplatin monotherapy as a first-line alternative
“An Australian retrospective study evaluated efficacy of carboplatin monotherapy (560 mg/m2 every 4 weeks) as a first line therapy in 104 patients treated between 1996 and 2013. Patients received a median of 12 doses and 86% of patients achieved disease stabilization or better (CR/PR/SD). A 5-year PFS was 51% with an excellent OS of 97%. Hypothalamic/chiasmatic location was identified as a main factor of poorer prognosis in regards to PFS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Hematological toxicity was predominant with grades 3 and 4 in 55/81 patients and allergic reaction occurred in 11% of patients” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Hence carboplatin monotherapy proved to be a possible alternative especially in very large regions with long-distance travels to the nearest oncology center. Moreover, there is no peripheral neuropathy risk compared to CV regimen.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Scale of SIOP-LGG 2004 and the proportion of registered children who received chemotherapy
“Total 3417 patients were enrolled between 2004 and 2012 in 118 institutions from 11 European countries. Out of 497 patients receiving chemotherapy, 249 were randomized to the CV arm.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Presence of diencephalic syndrome was identified as the strongest predicting factor for poor PFS and OS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Response rate at end of therapy with carboplatin and vincristine in COG A9952
“The overall response rate for CV arm was 50% at the end of therapy (MR 15%, PR 35%) with 5-year EFS 39%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Toxicity was moderately higher in the TPCV arm.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Duration and tolerability of first-line vinblastine
“The toxicity of vinblastine treatment was minimal, allowing most patients to complete the 70 weeks of treatment (one patient even extended treatment for two years without notable toxicities).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Only 2 patients received red blood cell transfusions, and no patient received platelet transfusions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Chemotherapy assignment and duration in the SIOP-LGG 2004 UK optic pathway glioma cohort
“Children received extended chemotherapy for 18 months. Children with NF1-OPGs received vincristine and carboplatin (VC). Children with sporadic OPGs were randomised to either VC alone or with etoposide.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One hundred seventy-three children with OPGs were enrolled from 21 UK paediatric oncology centres between 2004 and 2012 (Cancer Research UK trial number CRUK/05/012).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Carboplatin and vincristine doses differ between the North American and European regimens
“Interestingly, the administration schedule and carboplatin dosing differ between North America and Europe” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Northern American studies established the induction using carboplatin administered at a dose of 175 mg/m2 for 4 consecutive weeks, followed by a 2-week break, and then continued for 4 more weeks. Vincristine at a dose of 1.5 mg/m2 (maximum dose 2 mg) is administered for 10 weeks, concomitant with carboplatin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast to North American CV, carboplatin was administered at a higher dose (550 mg/m2) every 3–4 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Infusion schedules of the SIOP LGG 04 and monthly carboplatin protocols
“The SIOP LGG 04 protocol utilizes carboplatin in a dose of 550 mg/m2 infused over 1 hr on weeks 1, 4, 7, 10, 13, 17, 21, 25, and 6-weekly thereafter, along with vincristine weekly for 10 weeks followed by weeks 10, 13, 17, 21, and 25, and then 3 weeks in every 6 thereafter” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The protocol used for monthly carboplatin was described by Gururangan et al. in a phase II study and involves carboplatin in a dose of 560 mg/m2 infused over 1 hr every 4 weeks for 12 doses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Infusion times for the two protocols were identical (1 hr) as was pre- and post-hydration (30 min each). There was no routine use of corticosteroids or antihistamine in either protocol.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Vinblastine starting dose was maintained in a minority of participants
“The most frequent and important toxicity was hematological.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The initial dose appeared to be high, as only 24% of patients maintained the initial dose of vinblastine (6 mg/m2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, the recommended initial dose in future clinical trials after this study has been 5 mg/m2.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Choice of carboplatin over cisplatin and cisplatin dose reduction to limit hearing loss
“Young age at exposure (aged < 5 years) and high cumulative dose (> 400 mg/m2 cisplatin) further increase the risk of developing cisplatin-induced serious hearing loss” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For this reason, carboplatin has been used most often in the treatment of pediatric LGG with lesser risk of hearing loss” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If indicated, lowered doses of cisplatin were applied from 90 mg/m2 to 75 mg/m2 per course” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Monthly and weekly carboplatin doses and the planned duration of first-line treatment
“Several different carboplatin-based regimens were used over the study period. Carboplatin was administered either monthly (median dose, 560 mg/m2 per infusion) or weekly (175 mg/m2 per infusion) with or without vincristine with a planned duration of treatment ranging from 12 months to 18 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
RAF and MEK inhibitors
Dabrafenib plus trametinib versus carboplatin plus vincristine as first-line therapy in BRAF V600 pLGG
“A total of 110 patients underwent randomization (73 to receive dabrafenib plus trametinib and 37 to receive standard chemotherapy). At a median follow-up of 18.9 months, an overall response occurred in 47% of the patients treated with dabrafenib plus trametinib and in 11% of those treated with chemotherapy (risk ratio, 4.31; 95% confidence interval [CI], 1.7 to 11.2; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median progression-free survival was significantly longer with dabrafenib plus trametinib than with chemotherapy (20.1 months vs. 7.4 months; hazard ratio, 0.31; 95% CI, 0.17 to 0.55; P<0.001). Grade 3 or higher adverse events occurred in 47% of the patients receiving dabrafenib plus trametinib and in 94% of those receiving chemotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
FDA approval of dabrafenib plus trametinib for BRAF V600E pLGG
“On March 16, 2023, the U.S. Food and Drug Administration (FDA) approved dabrafenib in combination with trametinib (Tafinlar®, Mekinist®, Novartis Pharmaceuticals Corporation) for the treatment of pediatric patients with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This represents the first FDA approval of a systemic therapy for the first-line treatment of pediatric patients with LGG with a BRAF V600E mutation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Canadian consensus: upfront BRAF inhibitor with or without MEK inhibitor for BRAF V600E gliomas
“We suggest that most patients with BRAF V600E gliomas should be treated with BRAFis ± MEKis upfront. Discontinuation of treatment can be considered in certain circumstances, and we suggest a slow wean.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our group felt that, given the fact that some questions remain regarding the duration of treatment with targeted therapy and outcome at discontinuation, chemotherapy should not be removed from the treatment options and that a thorough discussion with the family is crucial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on clinical experience and consensus, we currently suggest treating with BRAFi ± MEKi for a total of 36 months for PLGG and 60 months for HGG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
European standard clinical practice: targeted therapy in the first line
Brazilian consensus: therapeutic recommendations for BRAF-altered LGG
“LGG8 | For low-grade gliomas with BRAF V600 mutations, inoperable or with residual lesion, or refractory/relapsed, consider combination therapy with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LGG9 | For low-grade gliomas with KIAA1549-BRAF fusion or wild-type BRAF, DO NOT use type 1 BRAF inhibitors (such as dabrafenib or vemurafenib).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LGG10 | For patients with low-grade gliomas that present with the KIAA1549-BRAF fusion, consider using tovorafenib as a therapeutic option.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Level of Agreement: 85%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, the panel recommended against the use of type I BRAF inhibitors (such as dabrafenib or vemurafenib) when a KIAA1549-BRAF fusion is detected, due to the risk of paradoxical MAPK pathway activation and subsequent tumor progression.25 For these patients, tovorafenib may represent an alternative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NCCN Guidelines for Pediatric Central Nervous System Cancers: scope
“The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Central Nervous System Cancers provide multidisciplinary diagnostic workup, staging, and treatment recommendations for diffuse high-grade gliomas and medulloblastomas in children and adolescents.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Selumetinib in recurrent or progressive pLGG: PBTC-029 phase 2 trial
“On stratum 1, 9/25 (36%) patients achieved a partial response (PR).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On stratum 3, 10/25 (40%) patients achieved a PR with a median follow-up of 48.6 months (8.6–59.1; IQR=12.2) for the 17 subjects without progressions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data not only provide an alternative to standard chemotherapy for these subgroups of patients, but this success has led to an interest in exploring efficacy in patients as a first-line therapy. In fact, these data have directly led to the development of two Children’s Oncology Group phase III studies in newly diagnosed pLGG patients both with and without NF1 comparing standard chemotherapy to selumetinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-five eligible and evaluable patients were enrolled with a median of 4 (1-11) previous therapies. Six of 25 (24%) had partial response, 14/25 (56%) had stable disease, and 5 (20%) had progressive disease while on treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selumetinib versus carboplatin and vincristine as first-line therapy: COG ACNS1831 and ACNS1833
“MEK inhibitors, including selumetinib, trametinib, mirdametinib, binimetinib, and cobimetinib, provide active inhibition of ERK signaling by targeting MEK, a kinase downstream from BRAF in the MAPK pathway. Several have been studied in pLGG, with demonstrated safety and efficacy data available in the recurrent pLGG and NF1-associated pLGG populations, and selumetinib is currently in clinical trials for newly diagnosed patients (NCT03871257, NCT04166409).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Selumetinib achieved objective response rates of 36–40% in recurrent or progressive pLGG [4]. This supported the initiation of a phase 3 trials (NCT04166409, NCT03871257) comparing selumetinib with standard chemotherapy in upfront settings that unfortunately closed early because of poor accrual [39].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Field | Registry record |
|---|---|
| Brief title | “A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma” |
| Overall status | “Active, not recruiting” |
| Field | Registry record |
|---|---|
| Brief title | “A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma” |
| Overall status | “Recruiting” |
Trametinib with or without dabrafenib in relapsed or refractory BRAF V600-mutant LGG
“In 49 patients with BRAF V600-mutant glioma (LGG, n = 47) across all four study parts, independently assessed objective response rates were 15% (95% CI, 1.9 to 45.4) for monotherapy (n = 13) and 25% (95% CI, 12.1 to 42.2) for combination (n = 36). Adverse event-related treatment discontinuations were more common with monotherapy (54% v 22%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While large, prospective trials are still ongoing (NCT03363217), retrospective analyses show promising objective response rates in recurrent pLGG, supporting drug class efficacy in this population (34–36). Interim results of a phase 2 study of single-agent trametinib demonstrated an overall response rate of around 47% (complete, partial, or minor response) in pLGG and a 60% response rate using volumetric assessments in patients with NF1-associated plexiform neurofibroma (33, 44).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Type II RAF inhibitor tovorafenib: current approval limited to relapsed or refractory disease
“On April 23, 2024, FDA granted accelerated approval to tovorafenib, a type II RAF kinase inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment exposure, discontinuation, and crossover in the first-line randomized comparison
“Twelve patients who were assigned to receive dabrafenib plus trametinib discontinued treatment, most commonly because of progressive disease (in 5 of 73 [7%]); in the chemotherapy group, 9 completed treatment and 16 discontinued, also most commonly because of progressive disease (in 9 of 37 [24%]). In the chemotherapy group, 9 patients had centrally confirmed progression and crossed over to receive dabrafenib plus trametinib.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median duration of exposure was 17.4 months with dabrafenib and 7.8 months with carboplatin; exposures to trametinib and vincristine were similar to those with dabrafenib and carboplatin, respectively” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dabrafenib plus trametinib in adults with recurrent BRAF V600E low-grade glioma in the ROAR basket trial
“In the low-grade glioma cohort, median follow-up was 32·2 months (IQR 25·1–47·8). Nine (69%; 95% CI 39–91) of 13 patients had an objective response by investigator assessment, including one complete response, six partial responses, and two minor responses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median duration of response by independent radiology review was 27·5 months (95% CI 3·8–39·5; six events [all progressions]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events led to dose reductions in 22 (38%) patients, interruptions in 24 (41%) patients, and permanent discontinuation in five (9%) patients” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Design, dosing, and statistical assumptions of the first-line randomized comparison
“Patients were randomly assigned in a 2:1 ratio to receive a combination of oral dabrafenib divided into two equal doses per day (<12 years of age, 5.25 mg per kilogram of body weight per day; ≥12 years of age, 4.5 mg per kilogram per day) plus trametinib once daily (<6 years of age, 0.032 mg per kilogram; ≥6 years, 0.025 mg per kilogram) or standard chemotherapy (carboplatin plus vincristine) according to the doses and schedule used in the Children’s Oncology Group A9952 trial.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Liquid formulations of dabrafenib and trametinib were available.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We estimated that the enrollment of 102 patients would provide at least 80% power to detect a relative increase of 30% in the overall response (which was estimated at 50% with dabrafenib plus trametinib and 20% with chemotherapy) in the primary analyses by independent assessment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sites, baseline histology, and participants randomized but not treated in the first-line comparison
“From September 2018 through December 2020, a total of 110 patients underwent randomization (73 to receive dabrafenib plus trametinib and 37 to receive chemotherapy) at 58 sites in 20 countries” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent investigator-determined histologic types of glioma were pilocytic astrocytoma (in 34 patients), ganglioglioma (in 30), low-grade glioma not otherwise specified (in 20), and pleomorphic xanthoastrocytoma (in 11).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Four patients in the chemotherapy group withdrew before receiving treatment on the basis of a decision by the parent or guardian (in 3 patients) or by the investigator (in 1 patient).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Deaths during the first-line randomized comparison
“No deaths were reported among the patients who received dabrafenib plus trametinib; 1 death was reported (from low-grade glioma) in the chemotherapy group. This death occurred more than 30 days after the last dose of randomized treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Population, prior therapy, and dosing in the ROAR low-grade glioma cohort
“In the low-grade glioma cohort, 13 patients were included in the ITT population. Median age was 33 years (range 18–58) and median time since diagnosis was 6·9 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All patients had previous surgery, eight (62%) had received previous radiotherapy, five (38%) had received previous chemotherapy, and two (15%) had received previous bevacizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients received oral dabrafenib (150 mg orally twice daily) and oral trametinib (2 mg orally once daily) until unacceptable toxicity, disease progression, or death.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events across the ROAR glioma cohorts
“The most common adverse events across both cohorts combined were fatigue (29 [50%] of 58), headache (25 [43%]), nausea (20 [34%]), and pyrexia (19 [33%]); 31 (53%) patients experienced grade 3 or 4 events, most commonly fatigue (five [9%]), decreased neutrophil count (five [9%]), headache (three [5%]), and neutropenia (three [5%]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Design of the TRAM-01 phase 2 basket trial of single-agent trametinib
“The primary objective is to determine the objective response rate of trametinib as a single agent for treatment of progressing/refractory tumors with MAPK/ERK pathway activation. The TRAM-01 study is a phase II multicentric open-label basket trial including four groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eligible patients for a given study group will receive daily oral trametinib at full dose for a total of 18 cycles of 28 days. A total of 150 patients will be enrolled in seven Canadian centers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Published 2024 update: first-line targeted therapy approvals and tovorafenib's regulatory designations, with unresolved duration and late-effect questions
Radiotherapy
European standard clinical practice: radiotherapy deferred, reserved for selected cases
NOPHO consensus guidelines on radiotherapy for pLGG
“Radiotherapy remains the most effective treatment for unresectable pLGG, but its use must be carefully weighed against the risk of long-term side effects. The guidelines emphasise a personalised treatment approach, considering the evolving field of targeted therapies and the importance of multidisciplinary input in decision-making.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Radiotherapy should generally be avoided when treating CNS tumours in NF1-patients as they have an increased risk of both developing secondary neoplasms [20] and vasculopathies [21].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Conformal radiotherapy outcomes: COG ACNS0221
Late cognitive and endocrine effects of conformal radiotherapy
“The effect of age exceeded that of radiation dose; patients younger than 5 years experienced the greatest decline in cognition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 10-year cumulative incidence of GH replacement was 48.9%; of thyroid hormone replacement, 64.0%; of glucocorticoid replacement, 19.2%; and of gonadotropin-releasing hormone analog therapy, 34.2%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Optic pathway and hypothalamic LGG: vasculopathy and second neoplasms after radiotherapy
“Possible RT-induced neoplasms developed in 8 patients, including 4 with NF-1. The 10-year cumulative incidence of clinically significant vasculopathy was 7.1% (95% CI, 2.9%-13.9%); vasculopathy did not develop in any child aged >10 years at the commencement of RT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term toxicity after photon radiotherapy
“Of the 23 survivors analyzed for late toxicity, 15 (65%) developed grade 3+ toxicity. The most common Common Terminology Criteria for Adverse Events grade 3 toxicity (30% of survivors) was serious cognitive disability. Four patients (14%) died secondary to treatment complications, all occurring over a decade after completing RT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Vision preservation with early radiotherapy in sporadic optic pathway glioma
Long-term survival without upfront radiotherapy and the trade-off against early tumor control
“Despite multiple progressions, we observed >90% survival 20 to 25 years after the diagnosis in the absence of aggressive modalities such as radiotherapy and no late mortality due to tumor progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Specifically, although radiotherapy may be associated with better tumor control in early years, it may lead to significant devastating sequelae affecting not only quality of life but also long-term survival during adult life.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity at last follow-up with early radiotherapy compared with chemotherapy
“At time of last follow-up, 70% of early RT patients maintained normal to satisfactory VA (≤0.2 LogMAR) in a minimum of 1 eye and 60% maintained it in both eyes versus 36% and 18% in the CT group, respectively (P = 0.03, P = .02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, in an analysis of all patients (N = 38) for clinical risk factors at diagnosis associated with poor long-term visual outcomes, the only statistically significant factors were blindness at presentation (P = .001) and <12 months of age at diagnosis (P = .04).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine supplementation and grade 3 toxicity after proton radiotherapy in sporadic optic pathway glioma
“As of last follow-up, 11 patients (58%) required post-RT hormonal supplementation. Of the 16 patients with long-term follow-up, 3 grade 3 toxicities were appreciated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One patient developed orbital edema and pain requiring surgical intervention; another 2 patients developed treatment-related vasculopathy (moyamoya disease) confirmed by angiography at 15 and 36 months from RT completion at 8 and 10 years old, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sources of bias in comparisons of upfront radiotherapy with nonradiation approaches
“Studies comparing patients who were irradiated upfront and patients subjected to nonradiation approaches are subject to a selection bias at several levels.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“First, upfront radiation treatment is currently reserved for more aggressive PLGG; this is highlighted by the early deaths (1-3 years after the diagnosis) observed in these cohorts” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Second, these are usually deep-seated tumors for which only a small biopsy sample is available; this leads to a biopsy bias, and presumably a low-grade glioma may actually represent a heterogeneous tumor with high- and low-grade components.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“An analysis of patients who survived 5 or more years bypasses many of these limitations and enables a more accurate analysis of late deaths possibly related to radiotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because no plateau has been reached, the impact of vascular events and tumor-related deaths may be even higher with longer follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Residual role for radiotherapy pending targeted therapy
“While awaiting future studies performed to identify the patients who may benefit from more intensive treatment and anticipating the introduction of targeted therapies, we acknowledge that radiation therapy may have a role in the management of selected, non-NF1 patients with refractory PLGG after careful consideration of alternative lines of chemotherapy, surgery, and targeted therapies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cerebrovascular events, moyamoya, and secondary meningioma after cranial irradiation
“After cranial irradiation, the risk of cerebrovascular incidents is increased 16% at age 50 to 26% at age 65” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The risk of developing Moyamoya is higher in younger children, in patients with optic pathway glioma, and in those receiving higher radiation doses and occurs at a median of 40-62 months after RT with median dose of 52 Gy (range, 23-150)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Latency periods for the development of secondary meningioma can be up to 20-40 years” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Disease control by modality in sporadic optic pathway glioma
“Patients undergoing initial treatment with RT experienced no progression at any time interval (100% progression-free survival [PFS]), and all patients had over 8 years of follow-up (Fig. 3A).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Two patients received MAPK/ERK kinase (MEK) inhibitors as first-line salvage and remain free from progression at 81 and 84 months. Three patients received temozolomide as first-line salvage with a median PFS of 19 months, whereas 20 patients received other chemotherapy (mostly vinblastine) with a median PFS of 9 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most progression overall was local; however, 4 patients in the CT group developed leptomeningeal disease during their disease course following repeated local failure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 19 patients eventually receiving RT, none progressed locally, and only the 1 above-mentioned patient progressed distantly, developing a new intracranial lesion months after treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Definition of the upfront radiotherapy analysis set and the late deaths within it
“To avoid bias, we excluded patients who had undergone gross total resection for PLGG because this is a curative intervention and abrogates the need for further radiation treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We also excluded patients who had died within the first 5 years after the diagnosis to avoid a potential biopsy bias of high-grade gliomas (which have an invariably aggressive course and, therefore, are more likely to require radiation therapy) misdiagnosed as PLGG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“To further explore this observation, we constructed a cohort of clinically relevant Ontario PLGG patients for whom total resection was not performed and who survived the first 5 years (whole Ontario cohort, n = 607; SickKids, n = 385). There were 32 late deaths overall (>5 years after diagnosis) recorded for the Ontario cohort with an SMR of 8.9 (95% CI, 6.1-12.2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Replication of the late mortality association in an independent SEER cohort
“The risk of late death for children undergoing radiation increased approximately 3-fold for all deaths (HR, 3.3; 95% CI, 2.3-4.7; P < .001) and tumor-related deaths (HR, 3.4; 95% CI, 2.1-5.5; P = .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Outcome of the four children with neurofibromatosis type 1 who received upfront radiotherapy
Twenty-year overall survival stratified by upfront radiotherapy
“Patients who received upfront radiation treatment showed significantly lower survival than those who did not (OS at 20 years, 76.9% ± 11.7% vs 96.9% ± 3.1%; P = .039; Supporting Fig. 4 [see online supporting information]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, for the SickKids cohort, the tumor-related survival was significantly inferior for patients who received upfront radiation (20-year OS, 87.4% ± 4.9%; SMR, 23.0; 95% CI, 10.9-39.4) versus those who did not (20-year OS, 97% ± 1.1%; SMR, 7.5; 95% CI, 4.1-12; P = .007; Fig. 2C), and upfront radiation treatment increased the risk of tumor-related death approximately 4-fold (HR, 4.4; 95% CI, 1.3-14.6; P = .013).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Twenty-year overall survival by radiotherapy in the SEER reference cohort
“For children who received upfront radiation and children who did not, the 20-year OS rates were 84.4% ± 1.9% and 95.3% ± 0.8%, respectively (P < .001; Fig. 2B). Similarly, the tumor-related 20-year OS rates were 89% ± 1.72% and 94.3% ± 0.8%, respectively (P < 0.001; Fig. 2D).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
First-line radiotherapy PFS in the German SIOP LGG 2004 trial and management-strategy comparison in Fisher's series
Limitations of current therapies
Summary: limitations of chemotherapy, radiotherapy, and approved targeted therapy
First-line chemotherapy controls disease in fewer than half of treated participants over 5 years. In COG A9952 (274 participants), 5-year event-free survival (EFS) was 39% with carboplatin plus vincristine, and in SIOP-LGG 2004 (497 participants) 5-year PFS was 46% with vincristine plus carboplatin; in a Canadian cohort of 54 participants, 5-year PFS with weekly vinblastine was 53.2%. Carboplatin hypersensitivity occurred in 44 of 105 participants (41.9%) in a Canadian retrospective series and in 47% of 34 participants in a single-institution series, and 24 of 34 rechallenged participants (70.5%) had recurrent reactions. Chemotherapy requires weekly intravenous administration over 60 to 81 weeks, with central venous catheters recommended for infants and toddlers. Visual acuity worsened in 41% of participants with NF1-associated optic pathway glioma and 39% with sporadic optic pathway glioma after chemotherapy in the SIOP-LGG 2004 UK cohort. BRAF V600E tumors have a 10-year PFS of 27% after chemotherapy or radiation therapy.
Radiotherapy is associated with cognitive decline in children younger than 5 years, a 10-year cumulative incidence of growth hormone replacement of 48.9%, vasculopathy, and second neoplasms. Dabrafenib plus trametinib is approved for first-line use only in BRAF V600E tumors, and type I BRAF inhibitors are not indicated in BRAF fusion tumors, which comprise approximately 35% of pLGG. No targeted therapy is approved for first-line treatment of BRAF fusion-driven pLGG. After discontinuation of BRAF inhibition, 13 of 17 participants (76.5%) with BRAF V600E pLGG progressed at a median of 2.3 months, and the optimal duration of targeted therapy is not established.
Carboplatin hypersensitivity reactions
“Forty-four patients (41.9%) developed Cb HSR after a median of 10.5 infusions (range, 3-39 infusions).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-four of 44 patients with Cb HSR were re-exposed to carboplatin, and 24 of 34 patients (70.5%) had recurrent Cb HSR.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Those patients treated with 4-weekly single agent carboplatin had carboplatin allergy in 8% of cases whereas 68% of those treated with combined carboplatin and vincristine (every three weeks, according to the SIOP 2004 low grade glioma protocol) had carboplatin reactions (OR 23.6, P < 0.01). Desensitization was only successful in two out of 10 patients in whom it was attempted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment burden: intravenous administration, visits, and central venous access
“Treatment with V/C or VBL may be accompanied by significant adverse effects, including bone marrow toxicity, neurotoxicity, hearing loss, renal dysfunction, and allergic reactions [3]. The burden of toxicity, frequent hospital visits as well as a significant number of patients progressing after first-line treatment, motivated the search for alternative strategies. In addition, these chemotherapy regimens appear even less effective in infants with pLGG [11]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Selumetinib requires monthly, shorter clinic visits and is taken orally with no requirement for central line placement as compared to weekly CV, bi-monthly bevacizumab/irinotecan and weekly vinblastine visits which often require a central line.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual outcomes after chemotherapy for optic pathway glioma
Poor chemotherapy outcomes in BRAF V600E pLGG
“Patients with BRAF V600E PLGG exhibited poor outcomes after chemotherapy and radiation therapies that resulted in a 10-year progression-free survival of 27% (95% CI, 12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E and wild-type PLGG, respectively (P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of approved targeted therapy: fusion tumors, rebound, and unknown duration
“The use of type I BRAF inhibitors is limited to patients with tumors harboring a BRAF V600E mutation due to the risk of paradoxical activation of the MAPK pathway and accelerated tumor growth if used in patients with tumors harboring a RAF fusion, such as those involving BRAF or CRAF/RAF1 [23].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, data generated from ongoing studies of various MAPK pathway inhibitors have shown that responses in pLGGs driven by either BRAF V600E mutations (treated with type I RAF inhibitors and/or MEK inhibitors) or KIAA1549::BRAF fusions (treated with MEK inhibitors) are often only durable for as long as the drug can be administered [27, 28].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After discontinuation of BRAF inhibition, 76.5% (13 of 17) of patients with PLGG experienced rapid progression (median, 2.3 months). However, upon rechallenge with BRAF inhibition, 90% achieved an objective response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While these treatments have heralded tremendous promise, challenges remain about how to best optimize their use, and the long-term toxicities associated with these inhibitors remain unknown.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the context of clinical paradigms favoring indefinite treatment, Dab-Tram is unlikely to prove cost-effective at the present price and would require a price reduction to facilitate sustained access.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Late effects of radiotherapy
“Cranial irradiation is also very effective against pLGG and has demonstrated improved PFS compared to conventional chemotherapy (62% versus 42% 10-year PFS compared to carboplatin/vincristine on HIT-LGG-1996) (13); however, radiation therapy is largely avoided in most sporadic pLGG and almost all NF1-associated pLGG due to the risk of significant late effects, including secondary malignancy, neurocognitive impairment, hormonal dysfunction, growth delay, vasculopathy and cerebrovascular injury (14–17).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Toxicity burden of first-line carboplatin and vincristine in the randomized comparison
“Carboplatin allergy was reported in 7 patients (21%) in the chemotherapy group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Permanent discontinuation because of adverse events was less common with dabrafenib plus trametinib than with chemotherapy (4% vs. 18%)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The frequency of adverse events leading to a dose adjustment or interruption was similar in the two groups: 79% with dabrafenib plus trametinib and 79% with chemotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Grade 3 and 4 toxicity and carboplatin allergy rates with carboplatin and vincristine
“Allergic reaction to carboplatin was observed in 26 patients, and those with grade 3 or 4 discontinued carboplatin therapy. Peripheral neuropathy grade 3 and 4 occurred in 19% of patients. Hematological toxicity accounted for most of the grade 3 and 4 adverse events, in particular decrease absolute neutrophil count (94%), decreased platelets (21%), and anemia (35%)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Toxicity profile was similar to the previous studies, most marked was carboplatin allergy affecting 53% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Carboplatin hypersensitivity reaction occurred in up to 68% of treated patients and posed significant challenge to CV regimen application. Patients experiencing grade 3 and 4 reaction were required to discontinue the therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Desensitization might provide some benefit to 20–73% of patients” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Progression-free survival falls with each subsequent line of chemotherapy
“However, Kandels et al. studied 96 patients who required second line chemotherapy. In this study, 3-year PFS for second line chemotherapy (28.1 ± 4.8%) was significantly lower when compared to first line chemotherapy (65.7 ± 2.7%). Progression-free survival rates declined with subsequent treatment-lines yet remaining higher for patients with NF1.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In non-NF1-associated tumors, vinblastine monotherapy vs platinum-based chemotherapy was noticeably less effective when used as second-line treatment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Duration of carboplatin-based treatment and the proportion needing further therapy
“Carboplatin was administrated monthly in 46 patients (43.8%) patients for a median total duration of 11 months (range, 1–20 months) and weekly in 59 patients (56.2%) for a total duration of 12 months (range, 0.7–20.9 months)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With a median follow-up of 5.1 years (range, 0.3–16.7 years) after diagnosis, 57 patients (54.3%) required further treatment for disease progression or relapse at a median of 21.3 months (range, 0.6–95.9 months).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes of carboplatin rechallenge with premedication or desensitization
“By using premedication alone, 10 patients (55.5%) were able to complete their carboplatin treatment, including 7 patients who had no further allergic manifestations (38.8%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median number of additional carboplatin infusions delivered with altering Cb HSR therapies was 4 (range, 0.5–34 additional infusions).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because of recurrent hypersensitivity symptoms despite altering Cb HSR therapies, carboplatin was discontinued in 20 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Such strategies are time consuming, costly, and add a significant burden and anxiety to the patient, family, and caregivers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Severity of carboplatin reactions and failure of a standard desensitization protocol
“Sixteen carboplatin hypersensitivity reactions were noted in the 34 children with low grade glioma. They occurred after a median of seven doses of carboplatin (range 3–14 doses). Three reactions were grade I allergic reaction, 10 were grade II allergic reaction, and three were grade III anaphylaxis according to CTCAE 4.0 criteria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Only two of 10 patients had no reaction to this rechallenge and one has since experienced a reaction, four doses after the successful rechallenge.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the eight patients with further reactions, two were grade III anaphylaxis requiring adrenaline, and the remainder were grade II requiring symptomatic management only.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Unknown long-term effects of targeted agents
“The late effects of these systemic target agents are largely unknown due to its recent application and need further awareness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MAPK inhibition and PAN RAF inhibition lead to side effects mainly concerning the skin, nails, hair, gastrointestinal tract, blood counts, risen CPK increased weight, while for PAN-RAF inhibition, temporary decreased growth velocity has been described” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Until now, these side effects seem to be transient, but should be followed further.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dose interruptions with each drug in the first-line randomized comparison
“Dose interruptions occurred in 56 of 73 patients (77%) receiving dabrafenib, 53 of 73 patients (73%) receiving trametinib, 23 of 33 patients (70%) receiving carboplatin, and 22 of 33 patients (67%) receiving vincristine” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Severity of the first carboplatin reaction and worsening on re-exposure
“Of the 44 children who developed Cb HSR, the severity of the first reaction was grade I or II in 36 patients (82%), grade III in 6 patients (13.6%), and grade IV in 2 patients (4.6%)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Upon re-exposure, 4 of 18 patients (22.2%) who received premedication alone and 7 of 12 patients (58.3%) who received both desensitization and premedication had worsening of their hypersensitivity symptoms” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“It is even more noteworthy that 32% of patients presented with a more severe reaction upon re-exposure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Limits of chemotherapy for preserving vision
“These findings raise the question as to whether chemotherapy is effective in preserving vision; it may well be that treatment after a certain point of visual deterioration cannot prevent further decline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A systematic review found that chemotherapy did not improve visual outcomes in 86% of children.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Timing of carboplatin hypersensitivity by schedule and its relation to cumulative exposure
“Cb HSR occurred significantly earlier during the weekly schedule, at median of 4.4 months (range, 0.4–15.4 months), compared with a median of 9.1 months (range, 3.1–14.6 months) on the monthly schedule (P = .02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The occurrence of hypersensitivity reaction was not related to a specific cumulative dose of carboplatin. The cumulative incidence of Cb HSR increased with the number of infusions without any plateau effect (Fig. 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Age, NF1 status, and tumor location were not associated with Cb HSR. The schedule of carboplatin administration (weekly or monthly) did not significantly influence the incidence of Cb HSR.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Severity of the first hypersensitivity reaction and the failure of prophylactic premedication
“Of the 44 children who developed Cb HSR, the severity of the first reaction was grade I or II in 36 patients (82%), grade III in 6 patients (13.6%), and grade IV in 2 patients (4.6%) (Table 4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Prophylactic premedication did not prevent Cb HSR significantly and did not influence the severity of the reaction (grade III and IV toxicity; 40% vs 15.3%; P = .22).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Desensitization outcomes and the regimens used after carboplatin was stopped
“Among the 12 patients who underwent desensitization and premedication, only 1 patient (8.3%) was able to complete his carboplatin therapy (P = .018).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Upon re-exposure, 4 of 18 patients (22.2%) who received premedication alone and 7 of 12 patients (58.3%) who received both desensitization and premedication had worsening of their hypersensitivity symptoms (P = .05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Four patients were observed without further chemotherapy, 2 patients underwent surgical resection, and 14 received another noncarboplatin-containing chemotherapy regimen, including 7 patients who received weekly vinblastine; 4 patients who received either combined thioguanine, procarbazine, and CCNU or combined thioguanine and PCV; and 3 patients who received another line of chemotherapy. The median duration of second-line chemotherapy was 7 months (range, 2–14 months). None of the patients received radiotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Progression during carboplatin treatment and total time on chemotherapy
“Fourteen (24.5%) progressions occured during administration of the carboplatin-based regimen.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median total duration of chemotherapy did not significantly differ for patients who did and did not experience Cb HSR (13.2 months and 11.3 months, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary: anticipated first-line position of tovorafenib
Current first-line systemic therapy for unresectable, progressive, or symptomatic pLGG is chemotherapy (carboplatin plus vincristine, or weekly vinblastine), except for BRAF V600E tumors, for which dabrafenib plus trametinib received FDA approval in March 2023 and is recommended upfront by Canadian consensus. European standard clinical practice recommendations (version dated December 2022) state that first-line targeted therapy is acceptable only within clinical trials. Tovorafenib is approved in the US (April 2024, accelerated approval) and the EU for relapsed or refractory pLGG with a BRAF fusion or rearrangement or BRAF V600 mutation; it is not approved for first-line use.
If LOGGIC/FIREFLY-2 is positive, tovorafenib would be positioned as first-line systemic therapy for participants aged 6 months to 25 years with RAF-altered pLGG that is unresectable and meets clinical or radiologic indications for treatment. The population with the largest unmet need is BRAF fusion-driven pLGG (KIAA1549::BRAF fusion in approximately 35% of pLGG), for which type I BRAF inhibitors are contraindicated and no targeted first-line therapy is approved; in BRAF V600E pLGG, tovorafenib would enter a setting with an approved targeted alternative. FIREFLY-2 excluded participants with NF1 and tumors with additional activating alterations (IDH1/2, histone H3, MYBL, FGFR), and FDA labeling carries a warning about potential growth of NF1-associated tumors, so NF1-associated pLGG is not an anticipated use. A Brazilian consensus published in 2026 already lists tovorafenib as a therapeutic option for KIAA1549-BRAF fusion LGG, with 85% agreement and without restriction to line of therapy.
Care is delivered in pediatric neuro-oncology centers with multidisciplinary tumor boards; FIREFLY-2 is conducted at academic centers (approximately 140 sites). Tovorafenib is an oral, once-weekly outpatient therapy that does not require central venous access, whereas chemotherapy comparators are given intravenously on a weekly schedule for 60 to 81 weeks. The primary FIREFLY-2 analysis is expected approximately 12 months after the last participant enrolled (May 2026), with preliminary results expected in 2027.
Current first-line landscape by molecular subgroup
“While chemotherapy remains front-line therapy for unresectable pLGG in most scenarios (with the notable exception of BRAF V600E-altered tumors), many patients recur following cytotoxic agents and require further treatment. Inhibitors of the MAPK pathway, primarily MEK and RAF kinase inhibitors, have emerged as effective and tolerable second-line or later therapy for pLGG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dabrafenib in combination with trametinib (D + T) was approved by FDA in 2023 for the first-line treatment of pediatric patients 1 year of age and older with LGG with a BRAF V600E mutation who require systemic therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prior to the approval of tovorafenib, there were no approved targeted therapies for patients with pLGG harboring BRAF fusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Molecularly based treatment strategies: first-line options by alteration
LOGGIC/FIREFLY-2: anticipated first-line population
“LOGGIC/FIREFLY-2 is a two-arm, randomized, open-label, multicenter, global, phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy vs. current standard of care (SoC) chemotherapy in patients < 25 years of age with pLGG harboring an activating RAF alteration who require first-line systemic therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, an indication for first-line systemic therapy is required, meaning that the tumor is non-resectable (either completely unresectable or partially resected with residual tumor that can no longer be resected) at the time of enrollment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with NF1-driven tumors are excluded. Furthermore, patients with a tumor exhibiting activating molecular alterations in addition to activating RAF alterations are also ineligible for participation even if the tumors are histologically of a low-grade.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who experience progressive disease in Arm 2 can crossover to Arm 1 and receive tovorafenib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory pathway: FIREFLY-2 as the confirmatory trial
“As a condition of accelerated approval, a confirmatory study to verify the clinical benefit of tovorafenib is required. FIREFLY-2 is an ongoing, international RCT that is being conducted in the front-line setting to compare tovorafenib to physician’s choice of chemotherapy in patients with pLGG with an activating RAF alteration who require systemic therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Off-label first-line use of MAPK inhibitors before phase 3 results
“Off-label use of MAPK pathway inhibitors, namely their use as first-line therapy in newly diagnosed patients with pLGG, is controversial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prior to the results of these trials and maturation of the longer-term data on late effects, the use of MAPK inhibitors as front-line therapy raises important ethical considerations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting: specialist multidisciplinary oversight
“The trial is being conducted at academic centers with patients being recruited from ~ 100 sites, including the SIOPe LOGGIC (Low Grade Glioma in Children) consortium in Europe, the Asia–Pacific region (Singapore, South Korea, Australia and New Zealand), and North America (Canada and the US).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting: oral outpatient therapy compared with intravenous chemotherapy
“Beyond convenience, oral MAPK inhibitors may also reduce financial toxicity for patients living in low resource or geographically limited areas, since on therapy monitoring necessitates fewer ambulatory office visits compared to a chemotherapy regimen administered weekly. Additionally, unlike chemotherapy, MAPK inhibitors are not associated with serious infectious complications since they do not cause significant myelosuppression or require central venous access, so unexpected hospital admissions are rare.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Specific socio-economic situations, such as patients living far away from hospitals, can impact the decision since it is generally easier to administer oral drugs at home with BRAFis with or without MEKis than weekly intravenous (IV) chemotherapy infusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proportion of children with a targetable alteration who actually received a targeted agent
“Interestingly, only 23% (18 of 78) of those received a targeted agent at some point during therapy. Of the remaining 60 patients with a targetable alteration, 30 underwent a curative total resection and were subsequently monitored.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, only 23% received a targeted agent. This may be partly explained by the fact that most patients who underwent curative surgery did not require further intervention. Moreover, targeted agents such as MEK inhibitors are not yet considered a first-line therapy and are often reserved for rapidly progressing tumors or clinical trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, for most patients, including ones who underwent a complete resection, a targeted agent has been identified for consideration at recurrence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Heterogeneity of treatment effect
Summary: factors that modify treatment effect
Molecular subgroup modifies outcomes with both chemotherapy and targeted therapy. BRAF V600E pLGG had a 10-year PFS of 27% after chemotherapy or radiation therapy versus 60.2% for wild-type tumors, and CDKN2A deletion independently predicted poor outcome; in a 1,000-tumor cohort, BRAF V600E with CDKN2A deletion had a 10-year PFS of 0%, whereas fusion-driven and NF1 tumors had a 10-year PFS of 67%. CDKN2A deletion was not associated with lack of response to BRAF inhibition. In FIREFLY-1 (relapsed or refractory), RANO-HGG objective response rate (ORR) was 69% for BRAF fusion and 50% for BRAF V600E tumors (10 evaluable participants), with a shorter median time to response for V600E tumors (2.8 versus 5.5 months by RAPNO). NF1-associated tumors were excluded from FIREFLY-1 and FIREFLY-2, and nonclinical data showed increased tumor volume in approximately 17% of NF1 model mice treated with tovorafenib; in contrast, participants with NF1 had better 5-year PFS with vinblastine (85.1% versus 42.0%) and had selumetinib response rates of 40%.
Age and tumor location also modify outcomes: younger age and tumor size greater than 3 cm2 predicted worse EFS in COG A9952, age and diencephalic syndrome predicted worse PFS and overall survival in SIOP-LGG 2004, and chemotherapy appears less effective in infants. FIREFLY-2 stratifies randomization by supratentorial midline location, fusion versus mutation, CDKN2A status, and infant chiasmatic-hypothalamic glioma. Visual outcomes after chemotherapy were poorer for sporadic than NF1-associated optic pathway glioma.
BRAF alteration type: tovorafenib response by fusion versus V600E in relapsed or refractory pLGG
“The ORR was 69% (95% CI: 56–81) in patients with tumors harboring BRAF fusions and 50% (95% CI: 19–81) in patients with tumors harboring BRAF V600E mutations. The ORR was 71% (95% CI: 54–84) in the 59% of evaluable patients who had received prior MAPK inhibitor (MAPKi) therapy and 61% (95% CI: 41–78) in those who had not.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median time to initial response (MR or PR) was 5.3 months (range, 1.6–11.2) overall; 2.8 months (range, 1.6–3.0) in patients with tumors harboring BRAF V600E mutations; and 5.5 months (range, 2.3–11.2) in patients with tumors harboring BRAF fusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exploratory subgroup analyses of ORR demonstrated similar response rates based on BRAF alteration (KIAA1549:BRAF fusion vs. BRAF V600E mutation), exposure to a prior MEK and/or BRAF inhibitor, and number of prior lines of therapy received.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NF1-associated tumors: exclusion and potential for tumor growth with tovorafenib
“In a neurofibromatosis type I (NF1) model without BRAF alteration, tovorafenib did not have antitumor activity, and while not statistically significant, an increase in tumor volume in ~17% of mice was observed with treatment (12).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although cases of patients with pLGG bearing both a BRAF alteration and loss of NF1 are rare, possible tumor growth in the context of NF-1 associated disease was considered relevant for clinician awareness (17).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NF1 status and outcomes with chemotherapy and MEK inhibition
“Patients with NF1 had a significantly better PFS (85.1%; 95% CI, 68.0% to 100%) when compared with patients without NF1 (42.0%; 95% CI, 29.1% to 60.7%; P = .012). Age< 3 years or > 10 years was not associated with poor outcome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this trial, there was no correlation between BRAF alterations and outcome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
BRAF V600E and CDKN2A deletion: prognosis with conventional therapy and response to BRAF inhibition
Molecular risk stratification
“pLGG harboring gene fusions or germline NF1 mutations comprise the low risk group. These tumors progress less frequently and often eventually stop growing with very few progressions seen after 10 years and almost no deaths at 20 years follow-up (10-year PFS of 67% and OS of 98%, 20-year PFS and OS of 58% and 96%, respectively) (Figure 7B–C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The intermediate risk group of pLGG includes tumors with BRAF p.V600E without CDKN2A deletion, FGFR1 SNV, IDH1 p.R132H or MET mutations. Intermediate risk tumors had a 10-year PFS and OS of 35% and 90%, respectively (Figure 7B–C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“High risk pLGG include those with H3.3 p.K27M, or BRAF p.V600E with CDKN2A deletion. These tumors almost invariably progress (10-year PFS of 0%) and these patients often succumb to their disease (10-year OS of 41%) (Figure 7B,C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age, tumor size, location, and diencephalic syndrome
Stratification factors in LOGGIC/FIREFLY-2
“Randomization between treatment arms will be stratified by primary location of the tumor (supratentorial midline vs. other), type of genomic RAF alteration (fusion vs. mutation), CDKN2A status (deletion vs. wild-type/unknown), and infant chiasmatic-hypothalamic glioma (CHG) diagnosis (yes vs. no).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Optic pathway glioma: NF1 status and visual outcome
“Children with and without NF1 demonstrated the same rate of VA improvement, stabilisation or worsening; however, children with sporadic OPG had a poorer VA outcome. Better initial VA, older age, absence of postchiasm tumour and presence of NF1 were associated with improved or stable VA outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Response by histologic subtype and CDKN2A status in first-line BRAF V600 pediatric low-grade glioma
“In addition, responses were observed across the diverse histologic types of glioma in this trial, findings that support broad use of dabrafenib plus trametinib as first-line therapy in this population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, among the patients for whom molecular data were available, responses were observed regardless of the presence or absence of CDKN2A homozygous deletion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Molecular subgroup and hemorrhage risk in pediatric low-grade glioma
“Six of 37 patients (16.2%) with KIAA1549::BRAF experienced a hemorrhage vs. 6 of 199 (3.0%) without known fusion” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“BRAF V600E mutation showed no association (0 hemorrhages among 28 patients, p = 0.996).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No hemorrhages occurred among patients with underlying genetic syndromes, including neurofibromatosis type 1 and tuberous sclerosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adjustment for KIAA1549::BRAF fusion substantially attenuated the apparent MAPK inhibitor effect (univariate HR 4.70 to adjusted HR 2.22, p = 0.260)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Per-eye visual acuity outcomes after chemotherapy in NF1-associated versus sporadic optic pathway glioma
“At initiation of chemotherapy, 26% and 49% of eyes in the NF1 and sporadic groups respectively had VA ≥0.7 logMAR” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At completion, in the NF1-OPG group, 49% of eyes had ≤0.2 logMAR, 23% of eyes had VA 0.30–0.60 logMAR and 28% of eyes had ≥0.70 logMAR. In the sporadic OPG group, 32% of eyes had ≤0.2 logMAR, 11% of eyes had 0.30–0.60 logMAR and 57% of eyes had ≥0.70 logMAR. Children with sporadic OPG, per eye, were significantly less likely to have a VA outcome of ≤0.60 logMAR compared with children with NF1-OPG (OR=0.30; 95% CI 0.16 to 0.56; P<0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Age and tumour location as predictors of visual outcome after chemotherapy
“Age ≤5 years (OR 25.2; 95% CI 3.02 to 209; P=0.003) and Dodge stage 3 (OR 7.14; 95% CI 2.44 to 25.0; P<0.001) at presentation were associated with VA ≥0.70 logMAR on both univariate and multivariate analysis in the NF1 group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In our NF1 cohort, children with Dodge stage 3 tumours were seven times more likely to experience worsening VA and a poor final VA outcome despite treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
Summary: care management for children receiving systemic therapy for pLGG
European standard clinical practice recommendations call for a multidisciplinary tumor board (neuro-oncology, neurosurgery, neurology, neuroradiology, radiotherapy, neuropathology) with involvement of ophthalmology, audiology, and endocrinology, and state that maintaining visual, endocrine, and neurological function is a key aspect of management. A 2026 Delphi consensus of 82 experts from 29 countries (funded by an educational grant from Day One Biopharmaceuticals) reached agreement on 50 of 129 statements, including that MAPK inhibitors should be prescribed and overseen by an oncology team in a multidisciplinary setting, that patient and caregiver education is essential, and that early prophylactic skin care is recommended; consensus was not reached for most cardiac, ophthalmologic, and endocrine statements. Recommended monitoring for MAPK inhibitors includes sodium and glucose in children with hypothalamic-pituitary lesions, echocardiography and ophthalmologic examination for MEK inhibitors, and height and growth velocity for tovorafenib. After discontinuation, structured imaging is recommended, particularly in the first 6 months, and Canadian consensus suggests MRI at least every 3 months for 1 year off therapy and slow tapering. Long-term visual monitoring and survivorship follow-up are supported by data showing that 26% of children with optic pathway glioma diagnosed before age 3 were bilaterally blind after a median of 11 years, and that adult survivors with bilateral blindness were more likely to be unemployed and to live with a caregiver.
Multidisciplinary tumor board and functional preservation
“All patients need comprehensive neuro-oncological care, the principles and details of which are summarized in the current guidelines. These represent standard of care for diagnostic work-up (including neuroimaging and neuropathology), and for therapeutic decisions (including the indications to non-surgical treatment) as well as concepts for neurosurgical intervention, chemotherapy and radiotherapy as well as surveillance and rehabilitation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Delphi consensus on adverse event management with MAPK inhibitors
“Of the 129 statements drafted, consensus (≥75% agreement) among 82 global experts in pLGG was reached for 50 statements, mostly pertaining to the general management of AEs occurring with MAPKi and the management of cutaneous AEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is also important that for all patients with pLGG in the suprasellar region, treatment should be started in consultation with the pediatric endocrinologist for adequate monitoring and guidance of growth and serum sodium values.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine monitoring during BRAF and MEK inhibitor therapy
“Clinicians using such treatments need to be aware of these potential effects, particularly the risk of hyponatraemia in patients with pre-existing central diabetes insipidus and monitor for these accordingly, including performing measurements of sodium and glucose prior to, during and after treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Growth monitoring during tovorafenib therapy
“Reduced growth velocity has been reported with tovorafenib, and recovery of growth velocity may occur after treatment interruption; therefore, baseline and longitudinal monitoring of height/weight percentiles and growth velocity should be incorporated into routine care, with pubertal assessment and endocrine evaluation when clinically indicated [73].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiac and ophthalmologic monitoring with MEK inhibitors
“While the rates of cardiac toxicity are low in children receiving MAPK pathway inhibitors in published reports, most guidelines recommend routine echocardiograms (ECHO) to monitor for asymptomatic diminishing ejection fraction (EF) while on MEK inhibitor therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Imaging surveillance and discontinuation of targeted therapy
“Since discontinuation of treatment can be associated with rapid clinical and radiological progression, we suggest tapering one drug at a time, starting with MEKis by approximately 25% every 3 months, and the BRAFis by 25% every 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest continuing with surveillance MRI at least every 3 months once off drugs for 1 year then as per institutional standard.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, approximately one-third of RR events (34.8%) were reported to be clinically symptomatic, whereas most were detected radiologically during routine surveillance. This finding underscores the importance of structured imaging follow-up, particularly during the first 6 months after MAPKi cessation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survivorship: vision loss and socioeconomic outcomes in adult survivors
“Among 1,233 survivors of childhood astroglial tumor ≥ 5 years post-diagnosis, 277 (22.5%) had visual impairment. In multivariable analysis, survivors with bilateral blindness were more likely to be unmarried (adjusted odds ratio [95% confidence interval]: 4.7 [1.5, 15.0]), live with a caregiver (3.1 [1.3, 7.5]), and be unemployed (2.2 [1.1, 4.5]) compared to those without visual impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survivorship: occupation, income, and education after radiotherapy
“On the long term, younger age at diagnosis and treatment with radiotherapy in LGG patients resulted in sevenfold lower occupation scores, more sheltered work, lower income, and less education in adulthood” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This lower occupation score was also related to vision, hearing, and motor impairments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Detection of hemorrhage and biology-informed surveillance in pediatric low-grade glioma
“Five of the twelve hemorrhages were symptomatic at presentation (three with headache alone, one with nausea and vomiting, and one with headache and vision impairment); the remaining seven were detected incidentally on surveillance imaging.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with KIAA1549::BRAF fusion, particularly those receiving MAPK inhibitors or requiring CSF diversion in high-risk locations, warrant heightened surveillance and careful procedural planning. Patients with genetic syndromes, BRAF V600E mutations, or tumors in non-eloquent locations without fusion carry substantially lower risk and may follow standard imaging protocols.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CSF diversion was independently associated with hemorrhage exclusively in high-risk anatomic locations (brainstem, optic pathway, hypothalamus), where it increased hemorrhage incidence sevenfold.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Management after carboplatin hypersensitivity: prophylaxis, discontinuation, and switching regimens
“Five of 15 patients who received prophylactic premedication developed Cb HSR (2 patients developed grade I Cb HSR, 1 patient developed grade II Cb HSR, and 2 patients developed grade III Cb HSR).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Four patients were observed without further chemotherapy, 2 patients underwent surgical resection, and 14 received another noncarboplatin-containing chemotherapy regimen, including 7 patients who received weekly vinblastine; 4 patients who received either combined thioguanine, procarbazine, and CCNU or combined thioguanine and PCV; and 3 patients who received another line of chemotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with carboplatin allergy, the current International Society of Pediatric Oncology LGG protocol discourages attempts to continue therapy by means of desensitization and suggests alternative combinations, such as vincristine plus cyclophosphamide or vincristine plus cisplatin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with an early onset allergic reaction, alternative chemotherapy regimens that offer a good efficacy rate without evidence of long-term toxicity should be considered instead.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Premedication and desensitization procedure used for carboplatin rechallenge
“All patients received premedication with dexamethasone (between 0.05 and 0.15 mg/kg delivered intravenously 1 hr prior to carboplatin) and cetirizine (approximately 0.2 mg/kg delivered orally 1 hr prior to carboplatin) and nine patients received a desensitization protocol with successive infusions of increasing doses as described by Confino-Cohen et al.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This protocol begins with premedication followed by infusion of 1/1000 of the total dose over 90 min followed by 1/100 of the total dose over 90 min followed by 1/10 of the total dose over 90 min followed by the remainder of the dose over 90 min.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Two of the patients with grade I reactions required no treatment; the other patient with a grade I reaction and the patients with grade II reactions responded promptly to steroid and antihistamine; and the patients with grade III anaphylaxis required adrenaline and responded promptly.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Senescence-associated secretory phenotype score as a possible guide to follow-up intensity
“These results could potentially have an impact on the therapeutic management and follow-up (FU) of these patient groups: (i) patients with a high or intermediate SASP sum score and GTR could potentially have longer FU intervals or even a shorter FU period overall; (ii) patients with initially subtotal resection and low or intermediate SASP sum score could benefit from a complete re-resection or possibly adjuvant therapy, to improve their PFS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The prognostic significance of the SASP sum score of course needs to be validated first in a prospective manner in upcoming clinical trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Accelerated approval postmarketing requirement 4608-1: randomized confirmatory trial
FDA review: FIREFLY-2 as the trial to verify clinical benefit
FDA listing of the confirmatory requirement in September 2026
Postmarketing requirements under 505(o): long-term growth, development, and gonadal toxicity
Postmarketing requirements under 505(o): carcinogenicity and drug interaction studies
Postmarketing commitments: FIREFLY-1 follow-up and CYP2C8 inducer study
Fulfilled requirements and open accelerated approval requirement in August 2025
European Union: specific obligations of the conditional marketing authorisation
European Union: CHMP view on FIREFLY-2 as the specific obligation
Ongoing post-approval monitoring
United States: periodic reporting on the confirmatory trial
United States: enhanced pharmacovigilance for wrong-dose medication errors
European Union: additional monitoring, periodic safety reports, and annual review
European Union: risk management plan safety concerns
| Category | Safety concern |
|---|---|
| Important identified risks | “Growth retardation” |
| Important identified risks | “Intratumoral haemorrhage” |
| Important potential risks | “Decreased fertility risk” |
| Missing information | “Long-term safety” |
European Union: long-term safety follow-up through FIREFLY-2
Expected outcomes of therapy
Summary: benchmarks for first-line therapy outcomes
Overall survival in pLGG is high regardless of first-line therapy (5-year overall survival 86% in COG A9952, 89% in SIOP-LGG 2004, and 94.4% with vinblastine), so expected benefits of new first-line therapy are measured by response, durability of disease control, and functional outcomes. Chemotherapy benchmarks are 5-year EFS of 39% (carboplatin plus vincristine, COG), 5-year PFS of 46% (vincristine plus carboplatin, SIOP), and 5-year PFS of 53.2% (vinblastine). In the only completed randomized first-line comparison of a targeted therapy (110 participants with BRAF V600 pLGG), dabrafenib plus trametinib produced an ORR of 47% versus 11% and a median PFS of 20.1 versus 7.4 months with carboplatin plus vincristine.
FIREFLY-2 was powered (approximately 400 participants, 85% power) to detect a 15% absolute improvement in ORR over an assumed 30% control-arm ORR, and a PFS hazard ratio of 0.67 based on an assumed median PFS of 4.5 years with tovorafenib versus 3 years with chemotherapy. In the relapsed or refractory setting (FIREFLY-1, 76 participants), tovorafenib produced an ORR of 51% by RAPNO criteria with a median duration of response of 13.8 months; among 35 participants with optic pathway glioma and at least 2 visual acuity assessments, visual acuity was preserved in 80% and improved in 31%. Visual acuity improved in 20% of participants with optic pathway glioma treated with first-line vinblastine and in 4 of 19 participants (21%) with recurrent optic pathway and hypothalamic glioma treated with selumetinib. In May 2026 the sponsor described the FIREFLY-2 primary endpoint as ORR based on RAPNO-LGG criteria, whereas the 2024 design publication specified RANO-LGG.
LOGGIC/FIREFLY-2: assumed outcomes underlying the sample size
“To assess the ORR per the primary endpoint, the planned sample size of approximately 400 patients will provide around 85% power to detect a 15% improvement for the tovorafenib arm at a two-tailed level of significance of 0.05, assuming a 30% ORR in the control arm and a dropout rate of up to 10%. To assess PFS as per the key secondary endpoint, the planned sample size of approximately 400 patients will provide around 85% power to detect a hazard ratio of 0.67 for PFS at a two-tailed level of significance of 0.05, assuming the median PFS for the tovorafenib arm is 4.5 years versus a median of three years for the control arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
LOGGIC/FIREFLY-2: endpoints as described at completion of enrollment
Functional outcomes assessed in LOGGIC/FIREFLY-2
“Importantly, this study also includes endpoints to evaluate improvements in neurologic outcomes, visual function in patients with optic pathway glioma (OPG), and patient-reported outcomes to better describe the overall impact on patients’ lives and activities of daily living.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Benchmark outcomes with first-line targeted therapy: dabrafenib plus trametinib
Benchmark outcomes with tovorafenib in relapsed or refractory pLGG
Visual outcomes with systemic therapy for optic pathway glioma
“VA per patient was preserved for 80% of patients; 31% demonstrated improved VA; VA per eye was preserved in 87%, with 27% improving.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity change during first-line dabrafenib plus trametinib versus carboplatin and vincristine
“The change from baseline in visual acuity was assessed in patients with tumors located near the optic chiasm (25 with dabrafenib plus trametinib and 11 with chemotherapy)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although visual acuity remained stable in most patients in the two groups, visual acuity per eye was improved in more patients who received dabrafenib plus trametinib than in those who received chemotherapy (14 of 41 eyes examined [34%] vs. 2 of 18 eyes examined [11%]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Landmark progression-free survival at 6 and 12 months with first-line dabrafenib plus trametinib versus chemotherapy
“At 6 months, the estimated progression-free survival was 87% (95% CI, 77 to 93) with dabrafenib plus trametinib and 58% (95% CI, 39 to 73) with chemotherapy; the percentages at 12 months were 67% (95% CI, 53 to 77) and 26% (95% CI, 10 to 46), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Discordance between imaging response and visual outcome in optic pathway glioma
“There was poor correlation between imaging and VA outcomes (n=66). Twenty-two per cent of patients with improved imaging outcomes had improved VA, whereas 30% of patients experienced worse VA despite improved or stable imaging outcomes” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There is however increasing evidence that serial changes in VA do not reliably detect tumour progression and, conversely, tumour progression does not reliably correlate with decreased VA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Outcome measures prioritized by clinicians and survivors
“The relevance of outcome measures after childhood cancer was recently investigated among 87 clinicians via two step Delphi questionnaire rounds and online focus groups of survivors” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For pediatric LGG, the fields of interest in late outcome were defined as motor function, vision, hypothalamic function, physical aspects, subsequent neoplasm, and psychosocial and neurocognitive aspects of quality of life besides overall survival and cause-specific mortality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment continued to loss of clinical benefit versus a fixed number of chemotherapy cycles
“Treatment was continued until loss of clinical benefit (as determined by the investigator), development of unacceptable toxic effects, initiation of a new anticancer therapy, completion of the protocol-defined number of cycles (in the chemotherapy group), loss to follow-up, or death.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Continuation of dabrafenib plus trametinib after investigator-determined disease progression was allowed if there was an expectation of continued clinical benefit.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Future studies are needed to evaluate functional outcomes (e.g., visual acuity), further molecular characterization, and most effective treatment duration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity preserved or improved in most children after first-line chemotherapy for optic pathway glioma
“With an average follow-up of 6.5 years, VA improved or remained stable in 59% and 61% of children with NF1 and sporadic OPGs, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although visual outcomes after chemotherapy are not optimal, timely treatment arrested the decline in VA in most children, and some children regained vision.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote